


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update July 20 - July 26, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 30 2020 829 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[New York Times - Corona update](#)

[New Treatment for Covid-19 Shows Promise, but Scientists Urge Caution](#)
[Pfizer Gets \\$1.95 Billion to Produce Coronavirus Vaccine by Year's End](#)
[Your Coronavirus Antibodies Are Disappearing. Should You Care?](#)
[The Doctor Behind the Disputed Covid Data](#)
[How to Test More People for Coronavirus Without Actually Needing More Tests](#)
[To Get People to Wear Masks, Look to Seatbelts, Helmets and Condoms](#)

[Washington Post - Corona update](#)

[Banks face a unique coronavirus problem: Now everyone is wearing a mask](#)
[As the pandemic surges, there are three scenarios of what happens next](#)
[Google employees will work from home until at least summer 2021](#)
[Coronavirus vaccine researchers: Making sure black and Hispanic communities are included in studies](#)
[North Korea locks down border city as first possible coronavirus case is announced](#)
[Houston, Miami, other cities face mounting health care worker shortages as infections climb](#)

[Guardian - Corona update](#)

[Will Covid-19 mutate into a more dangerous virus?](#)
[Coronavirus is the greatest global science policy failure in a generation](#)
[Fauci says Covid-19 vaccine is possible by October but more likely for November](#)
[Belgium PM warns country could go into second 'complete lockdown'](#)
[China is rewriting the facts about Covid-19 to suit its own narrative](#)

[Vit D deficiency more common among COVID-19 patients admitted to ICU \(Healio\)](#)
[Hydroxychloroquine not effective for mild to moderate COVID-19 \(Healio\)](#)
[Inhaled interferon beta shows promise for severe COVID-19 Healio\)](#)
[Researchers report 'extremely encouraging' COVID-19 vaccine data \(Healio\)](#)
[Fauci: 'The Virus Is a Formidable Foe' \(Medscape\)](#)
[Asymptomatic Infections, Antibodies in CSF \(Medscape\)](#)

Key Articles

- 1. Handyfuge-LAMP: low-cost and electricity-free centrifugation for isothermal SARS-CoV-2 detection in saliva., June 2020.** [medRxiv 2020](#); Ethan Li, Adam Larson, Anesta Kothari, Manu Prakash.
<https://www.medrxiv.org/content/10.1101/2020.06.30.20143255v1>
- 2. comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage.** [J. Clin. Lab. Anal. 2020:e23483](#)Zhao G, Su Y, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696465>
- 3. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain.** [J. Clin. Hypertens. \(Greenwich\) 2020](#); Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?>

term=32710674

4. **Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.** J. Thromb. Thrombolysis 2020; Marchandot B, Trimaille A, Curtiaud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696172>
5. **Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019.** Eur J Heart Fail 2020; Wei ZY, Qian HY, Huang J, Geng YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683753>
6. **Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).** Diabetes Metab Syndr 2020; 14:1225-1229 Subir R, Jagat JM, Kalyan KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683320>
7. **Worldwide maternal deaths due to COVID-19: A brief review.** Int J Gynaecol Obstet 2020; Nakamura-Pereira M, Andreucci CB, de Oliveira Menezes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706925>
8. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** Curr Atheroscler Rep 2020; 22:48 Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
9. **The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.** Clin Hypertens 2020; 26:14 McLachlan CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685191>
10. **COVID-19: Current prediction models unsuitable for practical use.** Deutsche Medizinische Wochenschrift 2020; 145:806-807 Lichert F.
11. **Thrombosis and coagulopathy in COVID-19: An illustrated review.** Res Pract Thromb Haemost 2020; 4:744-751 Levi M, Hunt BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685883>
12. **Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.** Int J Antimicrob Agents 2020:106101 Khuroo MS, Sofi AA, Khuroo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687949>
13. **COVID-19 and the kidney: what we think we know so far and what we don't.** J Nephrol 2020; Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691342>
14. **Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.** Transfus. Apher. Sci. 2020:102875 Abolghasemi H, Eshghi P, Cheraghali AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694043>

15. **Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.** Haematologica 2020; Perotti C, Baldanti F, Bruno R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32703797>
-

Basic Science (27 articles)

1. **Clinical Molecular Genetics Evaluation in Women with Reproductive Failures.** Am. J. Reprod. Immunol. 2020:e13313Bilal MY, Katara G, Dambaeva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710571>
2. **COVID-19: Current and future crisis planning in breast imaging.** Breast J 2020; Gerlach K, Phalak K, Patel M, Leung JWT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683734>
3. **Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: A case series.** Case Rep Womens Health 2020; 27:e00243Richtmann R, Torloni MR, Oyamada Otani AR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32704477>
4. **Berlin, April 22, 2020 - Don't be afraid of hospital treatment or hospital births in times of COVID-19.** Geburtshilfe Frauenheilkd. 2020; 80:579-580Scharl A, Albring C.
5. **Pregnancy, birth, and puerperium with SARS-CoV-2 and COVID-19.** Gynakologe 2020; Hagenbeck C, Pecks U, Fehm T *et al.*
6. **Contraceptive Mandate, ACA Final Rules, And COVID-19.** Health Aff (Millwood) 2020:101377Hlhaff202001265Keith K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687416>
7. **Third Trimester Placentas of SARS-CoV-2-Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization.** Histopathology 2020; Smithgall MC, Liu-Jarin X, Hamele-Bena D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692408>
8. **Providing women's health care during COVID-19: Personal and professional challenges faced by health workers.** Int J Gynaecol Obstet 2020; Green L, Fateen D, Gupta D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32692854>
9. **COVID-19 and obstetric practice: A critical review of the Nigerian situation.** Int J Gynaecol Obstet 2020; Ijarotimi OA, Ubom AE, Olofinbiyi BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698245>
10. **Worldwide maternal deaths due to COVID-19: A brief review.** Int J Gynaecol Obstet 2020; Nakamura-Pereira M, Andreucci CB, de Oliveira Menezes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706925>
11. **SARS-CoV-2 in pregnancy: characteristics and outcomes of hospitalized and non-hospitalized women due to COVID-19.** J Matern Fetal Neonatal Med 2020:1-7Barbero P, Muguerza L, Herraiz I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32689846>
12. **Vertical transmission of SARS CoV-2: a systematic review.** J Matern Fetal Neonatal Med 2020:1-8Deniz M, Tezer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693656>
13. **Perinatal management of SARS-CoV-2 infection in a level III University Hospital.** J Matern Fetal Neonatal Med 2020:1-4Pissarra S, Rosário M, Moucho M, Soares H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698646>
14. **Outcomes of universal SARS-CoV-2 testing program in pregnant women admitted to hospital and the adjuvant role of lung ultrasound in screening: A prospective cohort study.** J Matern Fetal Neonatal Med 2020:1-22Yassa M, Yirmibes C, Cavusoglu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691641>
15. **COVID-19 and pregnancy: an opportunity to correct an historic gender bias.** J Med Virol 2020; Comas C, Carreras E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706391>
16. **Feasibility and safety of urgently initiated maternal telemedicine in response to the spread of COVID-19: A 1-month report.** J. Obstet. Gynaecol. Res. 2020; Nakagawa K, Umazume T, Mayama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691488>
17. **Academic clinical learning environment in obstetrics and gynecology during the COVID-19 pandemic: responses and lessons learned.** J. Perinat. Med. 2020; Olson HL, Towner D, Hiraoka M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32692706>
18. **Coronavirus Disease 2019 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission.** J Reprod Infertil 2020; 21:157-168Ashraf MA, Keshavarz P, Hosseinpour P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32685412>
19. **Syndemic Perspectives to Guide Black Maternal Health Research and Prevention During the COVID-19 Pandemic.** Matern Child Health J 2020; Lemke MK, Brown KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696248>
20. **Statewide Implementation of Virtual Perinatal Home Visiting During COVID-19.** Matern Child Health J 2020; Marshall J, Kihlström L, Buro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691359>
21. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** Rev. Esp. Quimioter. 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
22. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** Rev. Esp. Quimioter. 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
23. **Interferon: the invisible link between COVID-19 and BCGitis female protection?** Scand. J. Immunol. 2020:e12939Di Bella S, Cabas P, Antonello RM, Rizzo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697854>

24. **Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol.** *Syst Rev* 2020; 9:161 Thomas B, Pallivalapila A, El Kassem W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682444>
25. **The Turkish Neonatal Society proposal for the management of COVID-19 in the neonatal intensive care unit.** *Turk Pediatri Ars* 2020; 55:86-92 Erdeve O, Cetinkaya M, Bas AY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684752>
26. **The Turkish Neonatal Society proposal for the management of COVID-19 in the neonatal intensive care unit.** *Turk Pediatri Ars* 2020; 55:86-92 Erdeve Ö, Çetinkaya M, Baş AY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684752>
27. **Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy.** *Women Birth* 2020; Ravaldi C, Wilson A, Ricca V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684343>

Biomarkers - Genetics (83 articles)

1. **ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.** *Ageing Res Rev* 2020:101123 Viana SD, Nunes S, Reis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683039>
2. **Distribution of SARS-CoV-2 PCR Cycle Threshold Values Provide Practical Insight Into Overall and Target-Specific Sensitivity Among Symptomatic Patients.** *Am J Clin Pathol* 2020; Buchan BW, Hoff JS, Gmehlin CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687186>
3. **Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study.** *Am. J. Med. Sci.* 2020; 360:120-128 Huang M, Yang Y, Shang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709280>
4. **Clinical Molecular Genetics Evaluation in Women with Reproductive Failures.** *Am. J. Reprod. Immunol.* 2020:e13313 Bilal MY, Katara G, Dambaeva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710571>
5. **Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm.** *Antioxidants (Basel)* 2020; 9:Fakhouri EW, Peterson SJ, Kothari J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708430>
6. **De Ritis ratio and biochemical parameters in COVID-19 patients.** *Arch. Physiol. Biochem.* 2020:1-5 Yazar H, Kayacan Y, Ozdin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683882>
7. **CRISPR/Cas as a Potential Diagnosis Technique for COVID-19.** *Avicenna J Med Biotechnol* 2020; 12:201-202 Dara M, Talebzadeh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695284>
8. **Evaluation of a novel blood microsampling device for clinical trial sample collection and protein biomarker analysis.** *Bioanalysis* 2020; Xing J, Loureiro J, Patel MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686955>
9. **Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents.** *Biochem. Biophys. Res. Commun.* 2020; 529:263-269 Irham LM, Chou WH, Calkins MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703421>
10. **Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Pandemic.** *Biology (Basel)* 2020; 9:Augustine R, Hasan A, Das S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707972>
11. **The role of hematological parameters in COVID-19 patients in the emergency room.** *Biomark. Med.* 2020; Usul E, Şan İ, Bekgöz B, Şahin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692248>
12. **Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases.** *Biomarkers* 2020:1-36 Kappert K, Jahić A, Tauber R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700561>
13. **Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19.** *Biosens. Bioelectron.* 2020; 166:112437 Zhu X, Wang X, Han L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692666>
14. **Scent dog identification of samples from COVID-19 patients - a pilot study.** *BMC Infect. Dis.* 2020; 20:536 Jendry P, Schulz C, Twele F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703188>
15. **Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19.** *Cancers (Basel)* 2020; 12: Duployez N, Demonchy J, Berthon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708264>
16. **Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes.** *Cells* 2020; 9:Ahmadi P, Hartjen P, Kohsar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707842>
17. **Hypoalbuminemia and elevated D-dimer in COVID-19 patients: a call for result harmonization.** *Clin Chem Lab Med* 2020; Aloisio E, Serafini L, Chibireva M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692697>
18. **Post-pandemic testing of SARS-CoV-2 in Huanan Seafood Market area in Wuhan, China.** *Clin Infect Dis* 2020; Li J, Wu C, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710746>
19. **Kidney disease and electrolytes in COVID-19: more than meets the eye.** *Clin Kidney J* 2020; 13:274-280 Carriazo S, Kanbay M, Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699613>
20. **Alteration of serum markers in COVID-19 and implications on mortality.** *Clin Transl Med* 2020:e119 Liu D, Li R, Yu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696591>
21. **Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis.** *Crit Care* 2020; 24:459 Chen XY, Huang MY, Xiao ZW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709251>
22. **Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19.** *Crit Care* 2020; 24:452 Kornilov SA, Lucas I, Jade K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698840>
23. **Haematological and immunological data of Chinese children infected with coronavirus disease 2019.** *Data Brief* 2020; 31:105953 Xiong X, Chua GT, Chi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685628>
24. **Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus.** *Diabetes Res Clin Pract* 2020:108351 Jing Liang J, Liu J, Chen Y *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711001>
25. **Lymphocyte subsets with the lowest decline at baseline and the slowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.** *Diabetes Res Clin Pract* 2020;108341 Liu D, Lan L, Luo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707212>
 26. **Analysis of the lymphocyte count in type 2 diabetic patients with coronavirus disease (COVID-19): A retrospective study in a centralized treatment center.** *Diabetes Res Clin Pract* 2020;108340 Wu D, Gao S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707213>
 27. **The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115130 Drew RJ, O'Donnell S, LeBlanc D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711184>
 28. **Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.** *EBioMedicine* 2020; 58:102916 Weiss A, Jellings M, Sommer MOA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711256>
 29. **Diagnostic groups and short-term outcomes in suspected COVID-19 cases treated in an emergency department.** *Emergencias* 2020; 32:242-252 Martín-Sánchez FJ, González Del Castillo J, Valls Carbó A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692001>
 30. **Coronaviruses in wastewater processes: Source, fate and potential risks.** *Environ Int* 2020; 143:105962 Amoah ID, Kumari S, Bux F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711332>
 31. **SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.** *Euro Surveill* 2020; 25:Fischer B, Knabbe C, Vollmer T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700672>
 32. **SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.** *Exp Hematol Oncol* 2020; 9:16 Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695551>
 33. **Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis.** *Front Cell Infect Microbiol* 2020; 10:364 Jesenak M, Brndiarova M, Urbancikova I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695683>
 34. **Regulatory Cross Talk Between SARS-CoV-2 Receptor Binding and Replication Machinery in the Human Host.** *Front. Physiol.* 2020; 11:802 Ahmed S, Paramasivam P, Raj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695025>
 35. **COVID-19, ACEI/ARBs and gastrointestinal symptoms: the jury is still out on the association.** *Gastroenterology* 2020; Parigi TL, Vespa E, Pugliese N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682762>
 36. **More reliability of suspicious symptoms plus chest CT-scan than RT-PCR test for the diagnosis of COVID-19 in an 18-days-old neonate.** *IDCases* 2020; 21:e00905 Mahdavi S, Kheirieh A, Daliri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685374>
 37. **Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review.** *Infect Dis Poverty* 2020; 9:100 Fakheran O, Dehghannejad M, Khademi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698862>
 38. **Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes.** *Int J Mol Sci* 2020; 21 Grobler C, Maphumulo SC, Grobbelaar LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708334>
 39. **Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic.** *Int J Mol Sci* 2020; 21 Rabiee N, Bagherzadeh M, Ghasemi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698479>
 40. **Role of neutrophil-lymphocyte-ratio in the mortality of males diagnosed with COVID-19.** *Iran J Microbiol* 2020; 12:194-197 Belice T, Demir I, Yuksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685114>
 41. **Role of neutrophil-lymphocyte-ratio in the mortality of males diagnosed with COVID-19.** *Iran J Microbiol* 2020; 12:194-197 Belice T, Demir I, Yuksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685114>
 42. **Tests with proven value in diagnosis of COVID-19.** *Iran J Microbiol* 2020; 12:261-262 Khan ZH, Samadi S, Makarem J, Mireskandari SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685124>
 43. **Comparison five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR.** *Iran J Microbiol* 2020; 12:185-193 Mollaei HR, Afshar AA, Kalantar-Neyestanaki D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685113>
 44. **Interleukin-6-based mortality risk model for hospitalised COVID-19 patients.** *J Allergy Clin Immunol* 2020; Rocio LG, Alberto UR, Paloma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710975>
 45. **Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: are we due for a second wave of COVID-19 in the fall?** *J Biol Regul Homeost Agents* 2020; 34 Goren A, Wambier CG, McCoy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700513>
 46. **Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.** *J Biomol Struct Dyn* 2020; 1-16 Razzaghi-Asl N, Ebadi A, Shahabipour S, Gholamin D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705953>
 47. **Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children.** *J. Clin. Invest.* 2020; Lee PY, Day-Lewis M, Henderson LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701511>
 48. **A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage.** *J. Clin. Lab. Anal.* 2020:e23483 Zhao G, Su Y, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696465>
 49. **The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.** *J Clin Med* 2020; 9 Villard O, Morquin D, Molinari N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708205>
 50. **My Experience with SARS-CoV-2, with a Focus on Testing.** *J. Clin. Microbiol.* 2020; 58 Cotter PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703893>
 51. **Special Issue on Diagnostic Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Lessons from This Pandemic.** *J. Clin. Microbiol.* 2020; 58 McAdam AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703896>

52. **Closing the Brief Case: "Not Positive" or "Not Sure"-COVID-19-Negative Results in a Symptomatic Patient.** J. Clin. Microbiol. 2020; 58Parikh BA, Bailey TC, Lyons PG, Anderson NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703892>
53. **The Brief Case: "Not Positive" or "Not Sure"-COVID-19-Negative Results in a Symptomatic Patient.** J. Clin. Microbiol. 2020; 58Parikh BA, Bailey TC, Lyons PG, Anderson NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703891>
54. **Improving the early diagnosis of suspected patients with COVID-19: a retrospective study of 106 patients.** J Infect Dev Ctries 2020; 14:547-553Gao X, Yang D, Yuan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683343>
55. **Comparing Chinese children and adults with RT-PCR positive COVID-19: A systematic review.** J Infect Public Health 2020; Pei Y, Liu W, Masokano IB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682658>
56. **Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older.** J Integr Med 2020; Dang JZ, Zhu GY, Yang YJ, Zheng F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690444>
57. **Outcomes of universal SARS-CoV-2 testing program in pregnant women admitted to hospital and the adjuvant role of lung ultrasound in screening: A prospective cohort study.** J Matern Fetal Neonatal Med 2020;1-22Yassa M, Yirmibes C, Cavusoglu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691641>
58. **How COVID-19 Is Testing and Evolving Our Communication Skills.** J Med Imaging Radiat Sci 2020; Julka-Anderson N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709543>
59. **Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: a systematic review and meta-analysis.** J Med Virol 2020; Bwire GM, Majigo MV, Njiro BJ, Mawazo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706393>
60. **Analysis of the positive rate of 4254 cases of COVID-19 nucleic acid tests in Different Sites in Wuhan, China.** J Med Virol 2020; Deng K, Li H, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691919>
61. **ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.** J Med Virol 2020; Torre-Fuentes L, Matías-Guiu J, Hernández-Lorenzo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691890>
62. **SARS-CoV-2 diagnostics in the virology laboratory of a University Hospital in Rome during the lockdown period.** J Med Virol 2020; Turriziani O, Sciandra I, Mazzuti L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697357>
63. **Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay.** J Med Virol 2020; Valdivia A, Torres I, Huntley D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706420>
64. **aThe dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19.** J Med Virol 2020; Zhou W, Xu X, Chang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706425>
65. **Arterial thromboembolism associated with COVID-19 and elevated D-dimer levels.** J Vasc Surg Cases Innov Tech 2020; 6:348-351Garg K, Barfield ME, Pezold ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704579>
66. **Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.** JCI Insight 2020; Wilson JG, Simpson LJ, Ferreira AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706339>
67. **Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.** Life Sci 2020;118102Jafarzadeh A, Chauhan P, Saha B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687918>
68. **A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.** Medicina (Kaunas) 2020; 56Marinaki S, Tsiakas S, Skalioti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708858>
69. **A Novel Multiplex qRT-PCR Assay to Detect SARS-CoV-2 Infection: High Sensitivity and Increased Testing Capacity.** Microorganisms 2020; 8Petrillo S, Carrà G, Bottino P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708870>
70. **COVID-19 and the Gut Microbiome: More than a Gut Feeling.** mSystems 2020; 5van der Lelie D, Taghavi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694127>
71. **SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically Confirmed Cases.** mSystems 2020; 5Wu F, Zhang J, Xiao A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694130>
72. **The Clinical and Radiological Manifestations in Coronavirus Disease 2019 With Negative Nucleic Acid Results.** Open Forum Infect Dis 2020; 7:ofaa252Lang G, Su J, Wu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704513>
73. **Willingness to Seek Diagnostic Testing for SARS-CoV-2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations.** Open Forum Infect Dis 2020; 7:ofaa269Siegler AJ, Hall E, Luisi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704517>
74. **Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications on its protein structure.** PeerJ 2020; 8:e9492Chand GB, Banerjee A, Azad GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685291>
75. **Screening testing for SARS-CoV-2 upon admission to rehabilitation hospitals in a high COVID-19 prevalence community.** Pm r 2020; Kirshblum SC, DeLauter G, Lopreiato MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700434>
76. **Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19.** Res Sq 2020; Farhadian S, Glick LR, Vogels CBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702723>
77. **Epidemiologic, Clinical, and Laboratory Findings of the COVID-19 in the current pandemic.** Res Sq 2020; Xie Y, Wang Z, Liao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702720>
78. **[Isolation of SARS-CoV-2 on reproductive tissue, a possible path of transmission.].** Rev. Esp. Salud Publica 2020; 94:e1-e2González-Castro A, Peñasco Y, Escudero-Acha P, Cuenca E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690859>
79. **Emergence of European and North American mutant variants of SARS-CoV-2 in Southeast Asia.** Transbound Emerg Dis 2020; Islam OK, Al-Emran HM, Hasan MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701194>

80. **Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.** *Transfus. Apher. Sci.* 2020;102871 Karataş A, İnkaya A, Demiroğlu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694044>
81. **Mild Cytokine Elevation, Moderate CD4(+) T Cell Response and Abundant Antibody Production in Children with COVID-19.** *Virol Sin* 2020; Jia R, Wang X, Liu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699972>
82. **Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity.** *Virol Sin* 2020; Kong WH, Zhao R, Zhou JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705575>
83. **Deploying Machine and Deep Learning Models for Efficient Data-Augmented Detection of COVID-19 Infections.** *Viruses* 2020; 12Sedik A, Iliyasu AM, Abd El-Rahiem B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708803>

Children (26 articles)

1. **Adolescent driving behavior before and during restrictions related to COVID-19.** *Accid. Anal. Prev.* 2020; 144:105686 Stavrinou D, McManus B, Mrug S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683132>
2. **American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1.** *Arthritis Rheumatol* 2020; Henderson LA, Canna SW, Friedman KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705809>
3. **American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.** *Arthritis Rheumatol* 2020; Wahezi DM, Lo MS, Rubinstein TB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705780>
4. **The neuropsychological impact of E-learning on children.** *Asian J Psychiatr* 2020; 54:102306 Jha AK, Arora A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688279>
5. **QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19.** *Cardiol. Young* 2020;1-15 Tuncer T, Karaci M, Boga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686633>
6. **Multi-Inflammatory Syndrome in Children related to SARS-CoV-2 in Spain.** *Clin Infect Dis* 2020; Moraleda C, Serna-Pascual M, Soriano-Arandes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710613>
7. **Complicated Appendicitis in a Pediatric Patient With COVID-19: A Case Report.** *Cureus* 2020; 12:e8677 Alsuwaillem AB, Turkistani R, Alomari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699677>
8. **Haematological and immunological data of Chinese children infected with coronavirus disease 2019.** *Data Brief* 2020; 31:105953 Xiong X, Chua GT, Chi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685628>
9. **Urticaria in an Infant with SARS-CoV-2 Positivity.** *Dermatol Ther* 2020:e14043 Proietti I, Mambrin A, Bernardini N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697027>
10. **Incidental lowering of otitis-media complaints in otitis-prone children during COVID-19 pandemic: not all evil comes to hurt.** *Eur. J. Pediatr.* 2020; Torretta S, Capaccio P, Coro I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691131>
11. **Comparing Chinese children and adults with RT-PCR positive COVID-19: A systematic review.** *J Infect Public Health* 2020; Pei Y, Liu W, Masokano IB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682658>
12. **Corona virus (Covid-19) - ITS implications in pediatric orthopedic care.** *J Orthop* 2020; 21:326-330 Lakhani A, Sharma E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684674>
13. **Trends in Pediatric Emergency Department Utilization after Institution of COVID-19 Mandatory Social Distancing.** *J. Pediatr.* 2020; Chaiyachati BH, Agawu A, Zorc JJ, Balamuth F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702427>
14. **Radiological Findings of COVID-19 in Children: A Systematic Review and Meta-Analysis.** *J. Trop. Pediatr.* 2020; Kumar J, Meena J, Yadav A, Yadav J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692815>
15. **COVID-19 pandemic: management of pediatric surgical patients: Statement of the German Society for Pediatric Surgery (DGKCH), the German Society of Pediatrics and Adolescent Medicine (DGKJ) and the German Society for Pediatric Infectious Diseases (DGPI).** *Monatsschr. Kinderheilkd.* 2020; Lange B, Tenenbaum T, Wessel LM.
16. **Psychological burden of quarantine in children and adolescents: A rapid systematic review and proposed solutions.** *Pak J Med Sci* 2020; 36:1106-1116 Imran N, Aamer I, Sharif MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704298>
17. **COVID-19 outbreak and pediatric diabetes: perceptions of health care professionals worldwide.** *Pediatr. Diabetes* 2020; Elbarbary NS, Dos Santos TJ, de Beaufort C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686287>
18. **Children and COVID-19: microbiological and immunological insights.** *Pediatr Pulmonol* 2020; Buonsenso D, Sali M, Pata D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710652>
19. **Insight into the Pediatric and Adult Dichotomy of COVID-19: Age-Related Differences in the Immune Response to SARS-CoV-2 infection.** *Pediatr Pulmonol* 2020; Fialkowski A, Gernez Y, Arya P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710693>
20. **Challenges to delivering pediatric surgery services in the midst of COVID 19 crisis: experience from a tertiary care hospital of Pakistan.** *Pediatr. Surg. Int.* 2020; Qazi SH, Saleem A, Pirzada AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691128>
21. **Clinical course of SARS-CoV-2 infection in children in Wuhan.** *Pneumologie* 2020; 74:322 Klein F.
22. **COVID-19 Pandemic-Related Practices and Policies Affecting the Continuity of Behavioral Health Care Among Children With Diabetes.** *Transl. Behav. Med.* 2020; Clary L, Wang C, Byrne ME, Monaghan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710626>
23. **Multisystem Inflammatory Syndrome in Children: Is There a Linkage to Kawasaki Disease?** *Trends Cardiovasc. Med.* 2020; Loke YH, Berul CI, Harahsheh AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702413>
24. **SARS-CoV-2 infection in children.** *Turk Pediatri Ars* 2020; 55:95-102 Cokugras H, Onal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684754>

25. **SARS-CoV-2 infection in children.** *Turk Pediatri Ars* 2020; 55:95-102Çokuğraş H, Önal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684754>
26. **Mild Cytokine Elevation, Moderate CD4(+) T Cell Response and Abundant Antibody Production in Children with COVID-19.** *Virol Sin* 2020; Jia R, Wang X, Liu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699972>

Clinical Features (42 articles)

1. **Higher frequency of hepatic steatosis at CT among COVID-19-positive patients.** *Abdom Radiol (NY)* 2020; Medeiros AK, Barbisan CC, Cruz IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683613>
2. **Higher frequency of hepatic steatosis at CT among COVID-19-positive patients.** *Abdom Radiol (NY)* 2020;1-7Medeiros AK, Barbisan CC, Cruz IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683613>
3. **Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study.** *Am. J. Med. Sci.* 2020; 360:120-128Huang M, Yang Y, Shang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709280>
4. **COVID-19 - associated urticaria with angioedema in a morbidly obese male successfully treated with glucocorticoids.** *Ann. Allergy. Asthma. Immunol.* 2020; Lockett RF, Hudey SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711028>
5. **Clinical characteristics of coronavirus disease 2019 in Gansu province, China.** *Ann Palliat Med* 2020; Yue H, Bai X, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692208>
6. **COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d'Andrologie de langue Française SALF).** *Basic Clin Androl* 2020; 30:10Hamdi S, Bendayan M, Huyghe E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685170>
7. **Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe.** *Cardiol Ther* 2020; Goel S, Jain T, Hooda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683639>
8. **Clinical and procedural characteristics of COVID-19 patients treated with percutaneous coronary interventions.** *Catheter. Cardiovasc. Interv.* 2020; Siudak Z, Grygier M, Wojakowski W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686899>
9. **Overview of Management of Children with COVID-19.** *Clin Exp Pediatr* 2020; Wati DK, Manggala AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683801>
10. **Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK.** *Clin Med (Lond)* 2020; Knights H, Mayor N, Millar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709637>
11. **Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary Care Hospital of Karachi.** *Cureus* 2020; 12:e8712Asghar MS, Haider Kazmi SJ, Ahmed Khan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699707>
12. **Epidemiological and Clinical Features of SARS-CoV-2: A Retrospective Study from East Karachi, Pakistan.** *Cureus* 2020; 12:e8679Tahir S, Tahir SA, Bin Arif T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699679>
13. **Urticaria in an Infant with SARS-CoV-2 Positivity.** *Dermatol Ther* 2020:e14043Proietti I, Mambrin A, Bernardini N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697027>
14. **COVID-19: Characteristics, ventilation and clinical courses of patients in Lombardy.** *Deutsche Medizinische Wochenschrift* 2020; 145:810Krome S.
15. **Demographic and Clinical Features of Critically Ill Patients with COVID-19 in Greece: The Burden of Diabetes and Obesity.** *Diabetes Res Clin Pract* 2020:108331Halvatsiotis P, Kotanidou A, Tzannis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682810>
16. **Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.** *EBioMedicine* 2020; 58:102916Weiss A, Jellingsø M, Sommer MOA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711256>
17. **Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments.** *Emergencias* 2020; 32:233-241Gil-Rodrigo A, Miró Ó, Piñera P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692000>
18. **Epidemiological and clinical course of 483 patients with COVID-19 in Wuhan, China: a single-center, retrospective study from the mobile cabin hospital.** *Eur J Clin Microbiol Infect Dis* 2020; Wang B, Wang Z, Zhao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683596>
19. **Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.** *Eur. J. Haematol.* 2020; Sanchez-Pina JM, Rodríguez Rodríguez M, Castro Quismondo N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710500>
20. **Conjunctivitis as sole symptom of COVID-19: A case report and review of literature.** *Eur. J. Ophthalmol.* 2020:1120672120946287Ozturker ZK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703010>
21. **COVID-19, Cilia, and Smell.** *Febs j* 2020; Li W, Li M, Ou G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692465>
22. **Late manifestation of follicular conjunctivitis in ventilated patient following COVID-19 positive severe pneumonia.** *Indian J Ophthalmol* 2020; 68:1675-1677Nayak B, Poddar C, Panigrahi MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709820>
23. **Clinical profile and prevalence of conjunctivitis in mild COVID-19 patients in a tertiary care COVID-19 hospital: A retrospective cross-sectional study.** *Indian J Ophthalmol* 2020; 68:1546-1550Sindhuja K, Lomi N, Asif MI, Tandon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709772>
24. **Epidemiological and Clinical Characteristics of Coronavirus Disease 2019 in Daegu, South Korea.** *Int J Infect Dis* 2020; Lee JY, Hong SW, Hyun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702415>
25. **Covid Toes: Phenomenon or Epiphenomenon?** *J Am Acad Dermatol* 2020; Deutsch A, Blasiak R, Keyes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682878>
26. **Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children.** *J. Clin. Invest.* 2020; Lee PY, Day-Lewis M, Henderson LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701511>
27. **Clinical Course and Outcomes of Severe Covid-19: A National Scale Study.** *J Clin Med* 2020; 9Amit M, Sorkin A, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708357>

28. **The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients.** J Clin Med 2020; 9:Stock da Cunha T, Gomá-Garcés E, Avello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708750>
29. **The Brief Case: "Not Positive" or "Not Sure"-COVID-19-Negative Results in a Symptomatic Patient.** J. Clin. Microbiol. 2020; 58:Parikh BA, Bailey TC, Lyons PG, Anderson NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703891>
30. **Comparing Chinese children and adults with RT-PCR positive COVID-19: A systematic review.** J Infect Public Health 2020; Pei Y, Liu W, Masokano IB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682658>
31. **Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older.** J Integr Med 2020; Dang JZ, Zhu GY, Yang YJ, Zheng F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690444>
32. **A Structural Equation Model to Examine the Clinical Features of Mild-to-Moderate Covid-19: A Multicenter Italian Study.** J Med Virol 2020; Barillari MR, Bastiani L, Lechien JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710639>
33. **Analysis of the positive rate of 4254 cases of COVID-19 nucleic acid tests in Different Sites in Wuhan, China.** J Med Virol 2020; Deng K, Li H, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691919>
34. **Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.** J Med Virol 2020; He J, Guo Y, Mao R, Zhang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691881>
35. **Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.** J Med Virol 2020; van Gerwen M, Alsen M, Little C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706392>
36. **The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections.** J Neuroimmune Pharmacol. 2020; Machhi J, Herskovitz J, Senan AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696264>
37. **Prospective study in 355 patients with suspected COVID-19 infection. Value of cough, subjective hyposmia, and hypogeusia.** Laryngoscope 2020; Martin-Sanz E, Riestra J, Yebra L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686164>
38. **Prospective study in 355 patients with suspected COVID-19 infection. Value of cough, subjective hyposmia, and hypogeusia.** Laryngoscope 2020; Martin-Sanz E, Riestra J, Yebra L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686164>
39. **Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.** Mult Scler Relat Disord 2020; 45:102414Mallucci G, Zito A, Fabbro BD, Bergamaschi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711296>
40. **Clinical course of SARS-CoV-2 infection in children in Wuhan.** Pneumologie 2020; 74:322Klein F.
41. **Epidemiologic, Clinical, and Laboratory Findings of the COVID-19 in the current pandemic.** Res Sq 2020; Xie Y, Wang Z, Liao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702720>
42. **Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy.** Support. Care Cancer 2020; Faria KM, Gomes-Silva W, Kauark-Fontes E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696245>

CNS (23 articles)

1. **Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.** Acta Neurol. Belg. 2020; Galassi G, Marchioni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696312>
2. **Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review.** Brain Behav Immun 2020; Egbert AR, Cankurtaran S, Karpiak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682993>
3. **Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis.** Clin Imaging 2020; 69:94-101Doo FX, Kassim G, Lefton DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707411>
4. **Clozapine in the Time of COVID-19.** Clin Psychopharmacol Neurosci 2020; 18:450-453Boland X, Dratcu L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702224>
5. **COVID-19, Cilia, and Smell.** Febs j. 2020; Li W, Li M, Ou G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692465>
6. **Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium.** Front. Neurol. 2020; 11:664Bhaskar S, Bradley S, Israeli-Korn S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695066>
7. **COVID-19 and olfactory dysfunction: A possible associative approach towards neurodegenerative diseases.** J. Cell. Physiol. 2020; Mahalaxmi I, Kaavya J, Mohana Devi S, Balachandar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697344>
8. **The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.** J. Neuroimmunol. 2020; 346:577323Ciardi MR, Zingaropoli MA, Pasculli P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688146>
9. **A systematic review of neurological symptoms and complications of COVID-19.** J. Neurol. 2020; Chen X, Laurent S, Onur OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691236>
10. **COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?** J. Neurol. 2020; Ferini-Strambi L, Salsone M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696341>
11. **COVID-19 in MS and NMO: A multicentric online national survey in Chile.** Mult Scler Relat Disord 2020; 45:102392Ciampi E, Uribe-San-Martin R, Soler B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683306>
12. **COVID-19 in MS and NMO: A multicentric online national survey in Chile.** Mult Scler Relat Disord 2020; 45:102392Ciampi E, Uribe-San-Martin R, Soler B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683306>
13. **COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.** Mult Scler Relat Disord 2020; 45:102402Fernández-Díaz E, Gracia-Gil J, García-García JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711297>

14. **Multiple sclerosis following SARS-CoV-2 infection.** *Mult Scler Relat Disord* 2020; 45:102377Palao M, Fernández-Díaz E, Gracia-Gil J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698095>
15. **Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak.** *Mult Scler Relat Disord* 2020; 45:102407Stojanov A, Malobabic M, Milosevic V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702641>
16. **Spinal nerve pathology in Guillain-Barré syndrome associated with COVID-19 infection.** *Muscle Nerve* 2020; Berciano J, Gallardo E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696462>
17. **Reply: 'Spinal nerve pathology in Guillain-Barré syndrome associated with COVID-19 infection'.** *Muscle Nerve* 2020; Oguz-Akarsu E, Ozpar R, Hakyemez B, Karli N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696488>
18. **COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.** *Neuroscientist* 2020;1073858420941476Kempuraj D, Selvakumar GP, Ahmed ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684080>
19. **COVID-19-associated encephalopathy: Neurological manifestation of COVID-19.** *Radiol Case Rep* 2020; 15:1646-1649Al Mazrouei SS, Saeed GA, Al Helali AA, Ahmed M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690988>
20. **Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings.** *Radiol Case Rep* 2020; 15:1591-1595AlKetbi R, AlNuaimi D, AlMulla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685076>
21. **Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19.** *Res Sq* 2020; Farhadian S, Glick LR, Vogels CBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702723>
22. **Neuropathogenic human coronaviruses: A review.** *Rev Med Virol* 2020:e02118Abdelaziz OS, Waffa Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687681>
23. **Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19.** *Seizure* 2020; 81:18-20Monti G, Giovannini G, Marudi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688169>

Complications (114 articles)

1. **Brugada syndrome.** *Acta Cardiol.* 2020:1-20Korlipara H, Korlipara G, Pentyala S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684122>
2. **A case of Inappropriate Antidiuretic Hormone Secretion Syndrome Associated with COVID-19 Pneumonia.** *Acta Endocrinol (Buchar)* 2020; 16:110-111Gemcioglu E, Karabuga B, Ercan A, Erden A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685049>
3. **Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions.** *Acta Med Port* 2020; Laires PA, Nunes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707029>
4. **Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.** *Acta Neurol. Belg.* 2020; Galassi G, Marchioni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696312>
5. **Treatment of acute respiratory failure in the course of COVID-19. Practical hints from the expert panel of the Assembly of Intensive Care and Rehabilitation of the Polish Respiratory Society.** *Adv Respir Med* 2020; 88:245-266Czajkowska-Malinowska M, Kania A, Kuca PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706108>
6. **Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4(+) T cell count.** *AIDS Res. Ther.* 2020; 17:46Menghua W, Xin Z, Jianwei L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703286>
7. **HIV and SARS-CoV-2: Intersecting Epidemics with Many Unknowns.** *Am. J. Epidemiol.* 2020; Lesko CR, Bengtson AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696057>
8. **Apical Takotsubo Cardiomyopathy in a COVID-19 Patient Presenting with Stroke: A Case Report and Pathophysiological Insights.** *Am J Med Case Rep* 2020; 8:350-357Kariyanna PT, Chandrakumar HP, Jayarangaiah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704530>
9. **Reply to: Fungal Infection During COVID-19: Does Aspergillus Mean Secondary Invasive Aspergillosis?** *Am J Respir Crit Care Med* 2020; van Arkel ALE, Rijpstra TA, Belderbos HNA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687390>
10. **Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei.** *Ann Palliat Med* 2020; Chen Y, Zhang K, Zhu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692230>
11. **American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1.** *Arthritis Rheumatol* 2020; Henderson LA, Canna SW, Friedman KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705809>
12. **American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.** *Arthritis Rheumatol* 2020; Wahezi DM, Lo MS, Rubinstein TB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705780>
13. **Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.** *Aust. Crit. Care* 2020; Chapple LS, Fetterplace K, Asrani V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682671>
14. **SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia.** *Biology (Base)* 2020; 9Pinto C, Berselli A, Mangone L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707770>
15. **Opening Pandora's box: surgical tracheostomy in mechanically ventilated COVID-19 patients.** *Br J Anaesth* 2020; El-Wajeh Y, Varley I, Raithatha A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709307>
16. **Interdependence between elevated intra-abdominal, pleural, and airway opening pressure in severe acute respiratory distress syndrome with extracorporeal membrane oxygenation.** *Br J Anaesth* 2020; Mauri T, Spinelli E, Caccioppola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682550>
17. **Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review.** *Brain Behav Immun* 2020; Egbert AR, Cankurtaran S, Karpiak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682993>

18. **Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis.** *Can J Kidney Health Dis* 2020; 7:2054358120938573Lim MA, Pranata R, Huang I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685180>
19. **Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19.** *Cancers (Basel)* 2020; 12Duployez N, Demonchy J, Berthon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708264>
20. **Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter?** *Cardiovasc Res* 2020; 116:e118-e121Smeda M, Chlopicki S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707576>
21. **Clinical and procedural characteristics of COVID-19 patients treated with percutaneous coronary interventions.** *Catheter. Cardiovasc. Interv.* 2020; Siudak Z, Grygier M, Wojakowski W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686899>
22. **The severe COVID-19: A sepsis induced by viral infection? and its immunomodulatory therapy.** *Chin. J. Traumatol.* 2020; Lin HY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690231>
23. **Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620943671Frydman GH, Boyer EW, Nazarian RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702995>
24. **Viral Coagulopathy in Patients With COVID-19: Treatment and Care.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620936776Kipshidze N, Dangas G, White CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687449>
25. **The extended autonomic system, dyshomeostasis, and COVID-19.** *Clin. Auton. Res.* 2020; Goldstein DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700055>
26. **Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study.** *Clin. Breast Cancer* 2020; Juanjuan L, Santa-Maria CA, Hongfang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709505>
27. **The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.** *Clin Hypertens* 2020; 26:14McLachlan CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685191>
28. **Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis.** *Clin Imaging* 2020; 69:94-101Doo FX, Kassim G, Lefton DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707411>
29. **Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury.** *Clin Kidney J* 2020; 13:362-370Kormann R, Jacquot A, Alla A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695327>
30. **Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury.** *Clin Kidney J* 2020; 13:269-273Ponce D, Balbi AL, Durand JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695319>
31. **Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019.** *Clin Kidney J* 2020; 13:354-361Rubin S, Orieux A, Prevel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695326>
32. **Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK.** *Clin Med (Lond)* 2020; Knights H, Mayor N, Millar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709637>
33. **Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.** *Clin Microbiol Infect* 2020; Langford BJ, So M, Raybardhan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711058>
34. **Complicated Appendicitis in a Pediatric Patient With COVID-19: A Case Report.** *Cureus* 2020; 12:e8677Alsuwailem AB, Turkistani R, Alomari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699677>
35. **A Case Report of Polymerase Chain Reaction-Confirmed COVID-19 in a Patient With Right Ventricular Thrombus and Bilateral Deep Vein Thrombosis.** *Cureus* 2020; 12:e8633Elkattawy S, Younes I, Noori MAM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685302>
36. **Extracorporeal Membrane Oxygenation Support in a Young Patient With COVID-19 Infection.** *Cureus* 2020; 12:e8694Lima G, Cardoso E, Paredes MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699691>
37. **ST Elevation in a Patient With COVID-19 Infection-Associated Fever: A Case of Brugada Pattern.** *Cureus* 2020; 12:e8722Mahadevaiah G, Aleem A, Secaira A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699717>
38. **Fatal Outcome in a Kidney-Pancreas Transplant Recipient With COVID-19.** *Cureus* 2020; 12:e8691Suwanwongse K, Shabarek N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699689>
39. **Disseminated Intravascular Coagulation: A Devastating Systemic Disorder of Special Concern with COVID-19.** *Dermatol Ther* 2020; Singh P, Schwartz RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700813>
40. **COVID-19: Characteristics, ventilation and clinical courses of patients in Lombardy.** *Deutsche Medizinische Wochenschrift* 2020; 145:810Krome S.
41. **COVID-19-associated coagulopathy.** *Diagnosis (Berl)* 2020; Franchini M, Marano G, Cruciani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683333>
42. **COVID-19 Pneumonia: Three Thoracic Complications in the Same Patient.** *Diagnostics (Basel)* 2020; 10Borghesi A, Aggiusti C, Farina D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698424>
43. **Kawasaki disease in siblings and a review of drug treatment.** *Drugs Context* 2020; 9Loo SK, Hon KL, Leung AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699547>
44. **Case Report of Acute Airway Obstruction Caused by Transglottic Squamous Carcinoma (Stage IV) During the Coronavirus Pandemic Cured by ECMO-Assisted Tracheostomy.** *Ear Nose Throat J* 2020; 145561320943354Chen Z, Lv Y, Feng Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687410>
45. **Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments.** *Emergencias* 2020; 32:233-241Gil-Rodrigo A, Miró Ó, Piñera P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692000>
46. **Clinical findings, risk factors, and final outcome in patients diagnosed with pulmonary thromboembolism and COVID-19 in hospital emergency departments.** *Emergencias* 2020; 32:253-257Jiménez Hernández S, Lozano Polo L, Suñen Cuquerella G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692002>

47. **Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era.** *eNeurologicalSci* 2020; 20:100256Shakibajahromi B, Borhani-Haghighi A, Haseli S, Mowla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704578>
48. **SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.** *Exp Hematol Oncol* 2020; 9:16Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695551>
49. **Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review.** *Heart Lung* 2020; Khatri A, Wallach F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693958>
50. **Acute abdomen -like-presentation associated with SARS-CoV-2 infection.** *IDCases* 2020; 21:e00895Ahmed AOE, Mohamed SF, Saleh AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691004>
51. **Bacterial and Fungal Co-Infections in COVID-19 Patients Hospitalized During the New York City Pandemic Surge.** *Infect Control Hosp Epidemiol* 2020:1-13Nori P, Cowman K, Chen V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703320>
52. **Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain.** *Int J Environ Res Public Health* 2020; 17Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709002>
53. **Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes.** *Int J Mol Sci* 2020; 21Grober C, Maphumulo SC, Grobbelaar LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708334>
54. **Acquired infection after intubating patients with COVID-19: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 67:110006Zhang J, Sun M, Li N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711351>
55. **Clinical Course and Outcomes of Severe Covid-19: A National Scale Study.** *J Clin Med* 2020; 9Amit M, Sorkin A, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708357>
56. **The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.** *J Clin Med* 2020; 9Villard O, Morquin D, Molinari N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708205>
57. **A case of severe psoriatic erythroderma with COVID-19.** *J Dermatolog Treat* 2020:1-11Ghalamkarpour F, Pourani MR, Abdollahimajid F, Zargari O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691645>
58. **COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges.** *J Fungi (Basel)* 2020; 6Mohamed A, Rogers TR, Talento AF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707965>
59. **A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy.** *J. Heart Lung Transplant.* 2020; Iacovoni A, Boffini M, Pidello S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709482>
60. **Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial study (COVID in Older PEople).** *J Hosp Infect* 2020; Carter B, Collins JT, Barlow-Pay F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702463>
61. **Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.** *J Infect Dis* 2020; Helleberg M, Niemann CU, Moestrup K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702095>
62. **Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China.** *J Int AIDS Soc* 2020; 23:e25568Guo W, Ming F, Feng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697865>
63. **Acute Kidney Injury and Kidney Damage in COVID-19 Patients.** *J Korean Med Sci* 2020; 35:e257Na KR, Kim HR, Ham Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686373>
64. **A Case Report of Tracheostomy for a Patient with COVID-19: How to Minimize Medical Staff and Patient Risks.** *J Korean Med Sci* 2020; 35:e263Youn SH, Baek SY, Yoon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686375>
65. **HIV/SARS-CoV-2 coinfection: a global perspective.** *J Med Virol* 2020; Kanwugu ON, Adadi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692406>
66. **SARS-CoV-2 infection in persons living with HIV: a single center prospective cohort.** *J Med Virol* 2020; Maggiolo F, Zoboli F, Arosio M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706409>
67. **Hemorrhagic encephalopathy associated with COVID-19.** *J. Neuroimmunol.* 2020; 346:577326Krett JD, Jewett GAE, Elton-Lacasse C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683185>
68. **Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104941Divani AA, Andalib S, Di Napoli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689643>
69. **Hemorrhagic stroke and anticoagulation in COVID-19.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104984Dogra S, Jain R, Cao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689588>
70. **Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104982Dumitrascu OM, Volod O, Bose S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689586>
71. **Cerebral venous thrombosis: A typical presentation of COVID-19 in the young.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104989Klein DE, Libman R, Kirsch C, Arora R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689590>
72. **Thalamic perforating artery stroke on computed tomography perfusion in a patient with coronavirus disease 2019.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104974Rudilosso S, Esteller D, Urrea X, Chamorro Á. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689589>
73. **Fibrinolysis and COVID-19: a tale of two sites?** *J Thromb Haemost* 2020; Keragala CB, Medcalf RL, Myles PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692877>
74. **Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrinolytic have a role in the early phases of coagulation disorders?** *J Thromb Haemost* 2020; Macciò A, Madeddu C, Caocci G, La Nasa G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692894>
75. **Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19.** *J Thromb Haemost* 2020; Patell R, Bogue T, Bindal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692862>
76. **The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience.** *J Thromb Haemost* 2020; Pesavento R, Ceccato D, Pasquetto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692874>

77. **COVID-19-associated vasculitis and vasculopathy.** *J. Thromb. Thrombolysis* 2020; Becker RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700024>
78. **Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.** *J. Thromb. Thrombolysis* 2020; Marchandot B, Trimaille A, Curtiaud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696172>
79. **Acute thrombotic events as initial presentation of patients with COVID-19 infection.** *J Vasc Surg Cases Innov Tech* 2020; 6:381-383Ilonzo N, Rao A, Berger K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704580>
80. **Severe immunosuppression and not a cytokine storm characterize COVID-19 infections.** *JCI Insight* 2020; Remy KE, Mazer M, Striker DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687484>
81. **Platelets to surrogate lung inflammation in COVID-19 patients.** *Med. Hypotheses* 2020; 143:110098Kuchi Bhotla H, Kaul T, Balasubramanian B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688185>
82. **Pneumothorax after COVID-19 pneumonia.** *MMW-Fortschritte der Medizin* 2020; 162:11Büttner R, Heiligensetzer A, Fürst A.
83. **Corona pandemic: Obesity increases risk of severe course of COVID-19.** *MMW-Fortschritte der Medizin* 2020; 162:32-33Müssig K.
84. **COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.** *Mult Scler Relat Disord* 2020; 45:102402Fernández-Díaz E, Gracia-Gil J, García-García JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711297>
85. **Multiple sclerosis following SARS-CoV-2 infection.** *Mult Scler Relat Disord* 2020; 45:102377Palao M, Fernández-Díaz E, Gracia-Gil J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698095>
86. **Spinal nerve pathology in Guillain-Barré syndrome associated with COVID-19 infection.** *Muscle Nerve* 2020; Berciano J, Gallardo E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696462>
87. **Reply: 'Spinal nerve pathology in Guillain-Barré syndrome associated with COVID-19 infection'.** *Muscle Nerve* 2020; Oguz-Akarsu E, Ozpar R, Hakyemez B, Karli N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696488>
88. **COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.** *Neuroscientist* 2020:1073858420941476Kempuraj D, Selvakumar GP, Ahmed ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684080>
89. **The Pandemic Academy: Reflections of Infectious Diseases Fellows During COVID-19.** *Open Forum Infect Dis* 2020; 7:ofaa256Beh DLL, Ng DHL, Ong SWX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704516>
90. **Prone Positioning of Patients With Acute Respiratory Distress Syndrome Related to COVID-19: A Rehabilitation-Based Prone Team.** *Phys Ther* 2020; Ng JA, Miccile LA, Iracheta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691056>
91. **Use of External Ventilator Control Panel for Mechanical Ventilation in Patients with Severe SARS-CoV-2 Infection.** *QJM* 2020; Austin A, Pezzano C, Lydon D, Chopra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692813>
92. **Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings.** *Radiol Case Rep* 2020; 15:1591-1595AlKetbi R, AlNuaimi D, AlMulla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685076>
93. **Rhabdomyolysis as a manifestation of a severe case of COVID-19: A case report.** *Radiol Case Rep* 2020; 15:1633-1637Husain R, Corcuera-Solano I, Dayan E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690987>
94. **COVID-19-associated acute pancreatitis: a rare cause of acute abdomen.** *Radiol Case Rep* 2020; 15:1601-1603Mazrouei SSA, Saeed GA, Al Helali AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685078>
95. **Thrombosis and thromboembolism related to COVID-19: A clarion call for obtaining solid estimates from large-scale multicenter data.** *Res Pract Thromb Haemost* 2020; 4:741-743Barco S, Konstantinides SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685882>
96. **Thrombosis and coagulopathy in COVID-19: An illustrated review.** *Res Pract Thromb Haemost* 2020; 4:744-751Levi M, Hunt BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685883>
97. **Venous thromboembolism in critically ill patients with COVID-19: Results of a screening study for deep vein thrombosis.** *Res Pract Thromb Haemost* 2020; 4:842-847Longchamp A, Longchamp J, Manzocchi-Besson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685893>
98. **Staying updated on COVID-19: Social media to amplify science in thrombosis and hemostasis.** *Res Pract Thromb Haemost* 2020; 4:722-726Makris M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685878>
99. **Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital.** *Res Pract Thromb Haemost* 2020; 4:835-841Nopp S, Janata-Schwartzek K, Prosch H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685892>
100. **Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital.** *Res Pract Thromb Haemost* 2020; 4:835-841Nopp S, Janata-Schwartzek K, Prosch H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685892>
101. **Antiviral anticoagulation.** *Res Pract Thromb Haemost* 2020; 4:774-788Prydzial ELG, Sutherland MR, Lin BH, Horwitz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685886>
102. **A proposal for staging COVID-19 coagulopathy.** *Res Pract Thromb Haemost* 2020; 4:731-736Thachil J, Cushman M, Srivastava A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685880>
103. **Respiratory support in patients with COVID-19 (outside intensive care unit). A position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases.** *Respir Med Res* 2020; 78:100768Rabec C, Gonzalez-Bermejo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707480>
104. **Continuously available ratio of SpO₂/FiO₂ serves as a noninvasive prognostic marker for intensive care patients with COVID-19.** *Respir Res* 2020; 21:194Lu X, Jiang L, Chen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698822>
105. **A case of non-severe COVID-19 complicated by pulmonary embolism.** *Respirol Case Rep* 2020; 8:e00622Akiyama Y, Horiuchi K, Kondo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685167>
106. **Prone cardiopulmonary resuscitation: A scoping and expanded grey literature review for the COVID-19 pandemic.** *Resuscitation* 2020; Douma MJ, Mackenzie E, Loch T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707142>

107. **High thrombus burden despite thrombolytic therapy in ST-elevation myocardial infarction in a patient with COVID-19.** *Rev Cardiovasc Med* 2020; 21:289-295Setia G, Tyler J, Kwan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706216>
108. **¿Are Superantigens the Cause of Cytokine Storm and viral sepsis in Severe COVID-19? Observations and hypothesis.** *Scand. J. Immunol.* 2020:e12944Scaglioni V, Soriano ER. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697367>
109. **Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19.** *Seizure* 2020; 81:18-20Monti G, Giovannini G, Marudi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688169>
110. **Infarction of the Splenium of the Corpus Callosum in the Age of COVID-19: A Snapshot in Time.** *Stroke* 2020:Strokeaha120030434Sparr SA, Bieri PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684144>
111. **Venous thromboembolism in non-critically ill patients with COVID-19 infection.** *Thromb Res* 2020; 193:166-169Trimaille A, Curtiaud A, Marchandot B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707275>
112. **Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide.** *Transpl Infect Dis* 2020:e13425Hu Q, Zhong Z, Xiong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702153>
113. **Kidney Transplant Recipients Infected By COVID-19: Review of the Initial Published Experience.** *Transpl Infect Dis* 2020:e13426Moris D, Kesseli SJ, Barbas AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702150>
114. **Influence of Immunosuppression on Seroconversion Against SARS-Cov-2 in Two Kidney Transplant Recipients.** *Transpl Infect Dis* 2020:e13423Wang AX, Quintero Cardona O, Ho DY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701196>

Cured – Recovered (6 articles)

1. **A case report of possible novel coronavirus 2019 reinfection.** *Am J Emerg Med* 2020; Duggan NM, Ludy SM, Shannon BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703607>
2. **Respiratory rehabilitation for post-COVID19 patients in spa centers: first steps from theory to practice.** *Int. J. Biometeorol.* 2020; Antonelli M, Donelli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710297>
3. **Planning for the Post-COVID Syndrome: How Payers Can Mitigate Long-Term Complications of the Pandemic.** *J Gen Intern Med* 2020; Jiang DH, McCoy RG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700223>
4. **Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic.** *Mult Scler Relat Disord* 2020; 45:102380Radulovic L, Erakovic J, Roganovic M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683304>
5. **Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China.** *Psychiatry Res* 2020; 292:113297Liu D, Baumeister RF, Veilleux JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707218>
6. **Recurrent positive nucleic acid detection in a recovered COVID-19 patient: A case report and literature review.** *Respir Med Case Rep* 2020; 31:101152Geling T, Huaizheng G, Ying C, Hua H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704471>

Cardiovascular disease (82 articles)

1. **Brugada syndrome.** *Acta Cardiol.* 2020:1-20Korlipara H, Korlipara G, Pentylala S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684122>
2. **ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.** *Ageing Res Rev* 2020:101123Viana SD, Nunes S, Reis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683039>
3. **Acute cardiac injury in patients with COVID-19.** *Am. J. Cardiovasc. Dis.* 2020; 10:28-33De Lorenzo A, Kasal DA, Tura BR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685261>
4. **Telecardiology during the Covid-19 pandemic: past mistakes and future hopes.** *Am. J. Cardiovasc. Dis.* 2020; 10:34-47De Simone V, Guarise P, Guardalben S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685262>
5. **Apical Takotsubo Cardiomyopathy in a COVID-19 Patient Presenting with Stroke: A Case Report and Pathophysiologic Insights.** *Am J Med Case Rep* 2020; 8:350-357Kariyanna PT, Chandrakumar HP, Jayarangaiah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704530>
6. **SARS-CoV-2 post-infective myocarditis: the tip of COVID-19 immune complications?** *Ann Intensive Care* 2020; 10:98Tissières P, Teboul JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705368>
7. **Early impact of the COVID-19 pandemic on acute stroke treatment delays.** *Can. J. Neurol. Sci.* 2020:1-15Neves Briard J, Ducroux C, Jacquin G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698917>
8. **QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19.** *Cardiol. Young* 2020:1-15Tuncer T, Karaci M, Boga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686633>
9. **Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter?** *Cardiovasc Res* 2020; 116:e118-e121Smeda M, Chlopicki S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707576>
10. **Clinical and procedural characteristics of COVID-19 patients treated with percutaneous coronary interventions.** *Catheter. Cardiovasc. Interv.* 2020; Siudak Z, Grygier M, Wojakowski W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686899>
11. **Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on a Tertiary-Level Electrophysiology Laboratory in Italy.** *Circ Arrhythm Electrophysiol* 2020; Compagnucci P, Volpato G, Pascucci R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703011>

12. **HRS/EHRA/APHS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic.** *Circ Arrhythm Electrophysiol* 2020; 13:e009007Varma N, Marrouche NF, Aguinaga L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692972>
13. **Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620943671Frydman GH, Boyer EW, Nazarian RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702995>
14. **Viral Coagulopathy in Patients With COVID-19: Treatment and Care.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620936776Kipshidze N, Dangas G, White CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687449>
15. **"Missing" acute coronary syndrome hospitalizations during the COVID-19 era in Greece: Medical care avoidance combined with a true reduction in incidence?** *Clin. Cardiol.* 2020; Papafaklis MI, Katsouras CS, Tsigkas G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691901>
16. **The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.** *Clin Hypertens* 2020; 26:14McLachlan CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685191>
17. **Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis.** *Clin Imaging* 2020; 69:94-101Doo FX, Kassim G, Lefton DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707411>
18. **A brand-new cardiorenal syndrome in the COVID-19 setting.** *Clin Kidney J* 2020; 13:291-296Apetrii M, Enache S, Siropol D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695320>
19. **Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?** *Clin Med (Lond)* 2020; Ladikou EE, Sivaloganathan H, Milne KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694169>
20. **A Case Report of Polymerase Chain Reaction-Confirmed COVID-19 in a Patient With Right Ventricular Thrombus and Bilateral Deep Vein Thrombosis.** *Cureus* 2020; 12:e8633Elkattawy S, Younes I, Noori MAM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685302>
21. **Spectrum of Cardiac Involvement in COVID-19.** *Cureus* 2020; 12:e8638Gill GS, Vlacancich R, Mehta N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685307>
22. **ST Elevation in a Patient With COVID-19 Infection-Associated Fever: A Case of Brugada Pattern.** *Cureus* 2020; 12:e8722Mahadevaiah G, Aleem A, Secaira A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699717>
23. **Disseminated Intravascular Coagulation: A Devastating Systemic Disorder of Special Concern with COVID-19.** *Dermatol Ther* 2020; Singh P, Schwartz RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700813>
24. **COVID 19: Autopsy study confirms lung damage and risk of thromboembolism.** *Deutsche Medizinische Wochenschrift* 2020; 145:807-808Krome S.
25. **Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).** *Diabetes Metab Syndr* 2020; 14:1225-1229Subir R, Jagat JM, Kalyan KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683320>
26. **Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?** *Diabetes Metab Syndr* 2020; 14:1241-1242Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683322>
27. **COVID-19-associated coagulopathy.** *Diagnosis (Berl)* 2020; Franchini M, Marano G, Cruciani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683333>
28. **Kawasaki disease in siblings and a review of drug treatment.** *Drugs Context* 2020; 9Loo SK, Hon KL, Leung AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699547>
29. **Clinical findings, risk factors, and final outcome in patients diagnosed with pulmonary thromboembolism and COVID-19 in hospital emergency departments.** *Emergencias* 2020; 32:253-257Jiménez Hernández S, Lozano Polo L, Suñen Cuquerella G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692002>
30. **Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era.** *eNeurologicalSci* 2020; 20:100256Shakibajahromi B, Borhani-Haghighi A, Haseli S, Mowla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704578>
31. **The detrimental effect of COVID-19 nationwide quarantine on accelerometer-assessed physical activity of heart failure patients.** *ESC Heart Fail* 2020; Vetrovsky T, Frybova T, Gant I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696600>
32. **Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019.** *Eur J Heart Fail* 2020; Wei ZY, Qian HY, Huang J, Geng YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683753>
33. **SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.** *Exp Hematol Oncol* 2020; 9:16Bao C, Tao X, Cui W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695551>
34. **Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients.** *Expert Rev. Cardiovasc. Ther.* 2020; Kow CS, Thiruchelvam K, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700573>
35. **COVID-19, ACEI/ARBs and gastrointestinal symptoms: the jury is still out on the association.** *Gastroenterology* 2020; Parigi TL, Vespa E, Pugliese N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682762>
36. **Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review.** *Heart Lung* 2020; Khatri A, Wallach F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693958>
37. **COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial Fibrillation.** *Int J Cardiol Heart Vasc* 2020; 29:100580Sattar Y, Connerney M, Ullah W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685662>
38. **Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain.** *Int J Environ Res Public Health* 2020; 17Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709002>
39. **Thrombosis centres and AVKs monitoring in COVID-19 pandemic.** *Intern Emerg Med* 2020; Barcellona D, Marongiu F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686059>

40. **Multimodality Imaging in Evaluation of Cardiovascular complications in Patients with COVID-19.** *J Am Coll Cardiol* 2020; Rudski L, Januzzi JL, Rigolin VH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710927>
41. **Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain.** *J. Clin. Hypertens. (Greenwich)* 2020; Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710674>
42. **A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy.** *J. Heart Lung Transplant.* 2020; Iacovoni A, Boffini M, Pidello S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709482>
43. **SARS-Cov-2 infection causes pulmonary shunt by vasodilatation.** *J Med Virol* 2020; Brito-Azevedo A, Pinto EC, de Cata Preta Corrêa GA, Bouskela E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706407>
44. **Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.** *J Med Virol* 2020; Liu X, Liu Y, Chen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687223>
45. **Hemorrhagic encephalopathy associated with COVID-19.** *J. Neuroimmunol.* 2020; 346:577326Krett JD, Jewett GAE, Elton-Lacasse C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683185>
46. **COVID-19 and stroke: Experience in a Ghanaian healthcare system.** *J Neurol Sci* 2020; 416:117044Sarfó FS, Mensah NO, Opoku FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702560>
47. **Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI.** *J Nucl Med* 2020; Skali H, Murthy VL, Paez D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709732>
48. **Systemic inflammation with cardiac involvement in pediatric patients with evidence of COVID-19 in a community hospital in the Bronx, NY.** *J Pediatric Infect Dis Soc* 2020; Rogo T, Mathur K, Purswani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687574>
49. **Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.** *J. Physiol.* 2020; Siri-Angkul N, Chattapakorn SC, Chattapakorn N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710575>
50. **Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104941Divani AA, Andalib S, Di Napoli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689643>
51. **Hemorrhagic stroke and anticoagulation in COVID-19.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104984Dogra S, Jain R, Cao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689588>
52. **Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104982Dumitrascu OM, Volod O, Bose S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689586>
53. **Optimization of resources and modifications in acute ischemic stroke care in response to the global COVID-19 pandemic.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104980Ford T, Curiale G, Nguyen TN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689645>
54. **Cerebral venous thrombosis: A typical presentation of COVID-19 in the young.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104989Klein DE, Libman R, Kirsch C, Arora R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689590>
55. **Thalamic perforating artery stroke on computed tomography perfusion in a patient with coronavirus disease 2019.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104974Rudilosso S, Esteller D, Urrea X, Chamorro Á. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689589>
56. **Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104953Siegler JE, Heslin ME, Thau L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689621>
57. **Fibrinolysis and COVID-19: a tale of two sites?** *J Thromb Haemost* 2020; Keragala CB, Medcalf RL, Myles PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692877>
58. **Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrinolytic have a role in the early phases of coagulation disorders?** *J Thromb Haemost* 2020; Macciò A, Madeddu C, Caocci G, La Nasa G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692894>
59. **Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19.** *J Thromb Haemost* 2020; Patell R, Bogue T, Bindal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692862>
60. **The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience.** *J Thromb Haemost* 2020; Pesavento R, Ceccato D, Pasquetto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692874>
61. **COVID-19-associated vasculitis and vasculopathy.** *J. Thromb. Thrombolysis* 2020; Becker RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700024>
62. **Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.** *J. Thromb. Thrombolysis* 2020; Marchandot B, Trimaille A, Curtiaud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696172>
63. **Arterial thromboembolism associated with COVID-19 and elevated D-dimer levels.** *J Vasc Surg Cases Innov Tech* 2020; 6:348-351Garg K, Barfield ME, Pezold ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704579>
64. **Acute thrombotic events as initial presentation of patients with COVID-19 infection.** *J Vasc Surg Cases Innov Tech* 2020; 6:381-383Ilonzo N, Rao A, Berger K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704580>
65. **Significant fall in stroke admissions in the Malopolska Voivodeship of Poland during the COVID-19 pandemic.** *Neurol. Neurochir. Pol.* 2020; Slowik A, Nowak R, Popiela T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700757>
66. **Electroencephalography during SARS-CoV-2 outbreak: practical recommendations from the task force of the Italian Society of Neurophysiology (SINC), the Italian League Against Epilepsy (LICE), and the Italian Association of Neurophysiology Technologists (AITN).** *Neurol Sci* 2020; Grippo A, Assenza G, Scarpino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696088>
67. **Thrombosis and thromboembolism related to COVID-19: A clarion call for obtaining solid estimates from large-scale multicenter data.** *Res Pract Thromb Haemost* 2020; 4:741-743Barco S, Konstantinides SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685882>

68. **Potential role of platelets in COVID-19: Implications for thrombosis.** *Res Pract Thromb Haemost* 2020; 4:737-740Koupenova M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685881>
69. **Thrombosis and coagulopathy in COVID-19: An illustrated review.** *Res Pract Thromb Haemost* 2020; 4:744-751Levi M, Hunt BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685883>
70. **Venous thromboembolism in critically ill patients with COVID-19: Results of a screening study for deep vein thrombosis.** *Res Pract Thromb Haemost* 2020; 4:842-847Longchamp A, Longchamp J, Manzocchi-Besson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685893>
71. **Staying updated on COVID-19: Social media to amplify science in thrombosis and hemostasis.** *Res Pract Thromb Haemost* 2020; 4:722-726Makris M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685878>
72. **Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital.** *Res Pract Thromb Haemost* 2020; 4:835-841Nopp S, Janata-Schwatzek K, Prosch H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685892>
73. **Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital.** *Res Pract Thromb Haemost* 2020; 4:835-841Nopp S, Janata-Schwatzek K, Prosch H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685892>
74. **Antiviral anticoagulation.** *Res Pract Thromb Haemost* 2020; 4:774-788Prydzial ELG, Sutherland MR, Lin BH, Horwitz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685886>
75. **A proposal for staging COVID-19 coagulopathy.** *Res Pract Thromb Haemost* 2020; 4:731-736Thachil J, Cushman M, Srivastava A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685880>
76. **A case of non-severe COVID-19 complicated by pulmonary embolism.** *Respirol Case Rep* 2020; 8:e00622Akiyama Y, Horiuchi K, Kondo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685167>
77. **Prone cardiopulmonary resuscitation: A scoping and expanded grey literature review for the COVID-19 pandemic.** *Resuscitation* 2020; Douma MJ, Mackenzie E, Loch T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707142>
78. **High thrombus burden despite thrombolytic therapy in ST-elevation myocardial infarction in a patient with COVID-19.** *Rev Cardiovasc Med* 2020; 21:289-295Setia G, Tyler J, Kwan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706216>
79. **Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology.** *Rev Esp Cardiol (Engl Ed)* 2020; Vivas D, Roldán V, Esteve-Pastor MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694078>
80. **COVID-19-Related Cardiovascular Disease and Practical Considerations for Perioperative Clinicians.** *Semin. Cardiothorac. Vasc. Anesth.* 2020;1089253220943019Gerstein NS, Venkataramani R, Goumas AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706293>
81. **Venous thromboembolism in non-critically ill patients with COVID-19 infection.** *Thromb Res* 2020; 193:166-169Trimaille A, Curtiaud A, Marchandot B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707275>
82. **Multisystem Inflammatory Syndrome in Children: Is There a Linkage to Kawasaki Disease?** *Trends Cardiovasc. Med.* 2020; Loke YH, Berul CI, Harahsheh AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702413>

Diagnosis (11 articles)

1. **Post-pandemic testing of SARS-CoV-2 in Huanan Seafood Market area in Wuhan, China.** *Clin Infect Dis* 2020; Li J, Wu C, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710746>
2. **Diagnostic groups and short-term outcomes in suspected COVID-19 cases treated in an emergency department.** *Emergencias* 2020; 32:242-252Martín-Sánchez FJ, González Del Castillo J, Valls Carbó A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692001>
3. **Virology, pathogenesis, diagnosis and in-line treatment of COVID-19.** *Eur. J. Pharmacol.* 2020;173375Samudrala PK, Kumar P, Choudhary K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682788>
4. **My Experience with SARS-CoV-2, with a Focus on Testing.** *J. Clin. Microbiol.* 2020; 58Cotter PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703893>
5. **Special Issue on Diagnostic Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Lessons from This Pandemic.** *J. Clin. Microbiol.* 2020; 58McAdam AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703896>
6. **Closing the Brief Case: "Not Positive" or "Not Sure"-COVID-19-Negative Results in a Symptomatic Patient.** *J. Clin. Microbiol.* 2020; 58Parikh BA, Bailey TC, Lyons PG, Anderson NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703892>
7. **The Brief Case: "Not Positive" or "Not Sure"-COVID-19-Negative Results in a Symptomatic Patient.** *J. Clin. Microbiol.* 2020; 58Parikh BA, Bailey TC, Lyons PG, Anderson NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703891>
8. **The COVID-19 Diagnostic Dilemma: a Clinician's Perspective.** *J. Clin. Microbiol.* 2020; 58Rogers R, O'Brien T, Aridi J, Beckwith CG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703894>
9. **Improving the early diagnosis of suspected patients with COVID-19: a retrospective study of 106 patients.** *J Infect Dev Ctries* 2020; 14:547-553Gao X, Yang D, Yuan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683343>
10. **Comparing Chinese children and adults with RT-PCR positive COVID-19: A systematic review.** *J Infect Public Health* 2020; Pei Y, Liu W, Masokano IB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682658>
11. **COVID-19: Progress in diagnostics, therapy and vaccination.** *Theranostics* 2020; 10:7821-7835Liu X, Liu C, Liu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3268502>

DM-MS-Obesity (25 articles)

1. **Issues for the management of people with diabetes and COVID-19 in ICU.** *Cardiovasc. Diabetol.* 2020; 19:114Ceriello A, Standl E, Catrinou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690029>

2. **Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.** *Cardiovasc. Diabetol.* 2020; 19:115Longo M, Caruso P, Maiorino MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698837>
3. **Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 α /Glycolysis-Dependent Axis.** *Cell Metab.* 2020; Codo AC, Davanzo GG, Monteiro LB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697943>
4. **COVID-19 and Diabetes: Insulin Requirements Parallel Illness Severity in Critically Unwell Patients.** *Clin. Endocrinol. (Oxf.)* 2020; Wu L, Girgis CM, Cheung NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683745>
5. **Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes.** *Diabetes Metab Res Rev* 2020:e3388Al-Salameh A, Lanoix JP, Bennis Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683744>
6. **Diabetes and COVID-19: A systematic review on the current evidences.** *Diabetes Res Clin Pract* 2020:108347Abdi A, Jalilian M, Ahmadi Sarbarzeh P, Vlasisavljevic Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711003>
7. **Impact of covid-19 lockdown on glycemic control in patients with type 1 diabetes.** *Diabetes Res Clin Pract* 2020:108348Fernández E, Cortazar A, Bellido V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711000>
8. **Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis.** *Diabetes Res Clin Pract* 2020:108346Guo L, Shi Z, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710998>
9. **Demographic and Clinical Features of Critically Ill Patients with COVID-19 in Greece: The Burden of Diabetes and Obesity.** *Diabetes Res Clin Pract* 2020:108331Halvatsiotis P, Kotanidou A, Tzannis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682810>
10. **Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus.** *Diabetes Res Clin Pract* 2020:108351Jing Liang J, Liu J, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711001>
11. **Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.** *Diabetes Res Clin Pract* 2020:108341Liu D, Lan L, Luo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707212>
12. **Knowledge, attitudes and practices towards COVID-19 among young adults with Type 1 Diabetes Mellitus amid the nationwide lockdown in India: A cross-sectional survey.** *Diabetes Res Clin Pract* 2020:108344Pal R, Yadav U, Grover S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710997>
13. **Recommendations and management of hyperglycaemia in pregnancy during COVID-19 pandemic in Italy.** *Diabetes Res Clin Pract* 2020:108345Torlone E, Angela Sculli M, Bonomo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710999>
14. **Analysis of the lymphocyte count in type 2 diabetic patients with coronavirus disease (COVID-19): A retrospective study in a centralized treatment center.** *Diabetes Res Clin Pract* 2020:108340Wu D, Gao S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707213>
15. **Perceived Risk, Behavior Changes and Health-related Outcomes During COVID-19 Pandemic: Findings among Adults with and without Diabetes in China.** *Diabetes Res Clin Pract* 2020:108350Yan AF, Sun X, Zheng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710996>
16. **Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach.** *Diabetes Ther.* 2020; Attri B, Goyal A, Gupta Y, Tandon N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683660>
17. **Mechanism of higher risk for COVID-19 in diabetes: a mask to lift.** *Endocrine* 2020; Fang C, Huang Y, Guo H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705411>
18. **Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis.** *Environ. Sci. Pollut. Res. Int.* 2020; Malik VS, Ravindra K, Attri SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710359>
19. **Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns.** *J Clin Med* 2020; 9Koliaki C, Tentolouris A, Eleftheriadou I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708504>
20. **Newly diagnosed diabetes mellitus, DKA and COVID-19: causality or coincidence? - A report of 3 cases.** *J Med Virol* 2020; Suwanwongse K, Shabarek N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706395>
21. **Corona pandemic: Obesity increases risk of severe course of COVID-19.** *MMW-Fortschritte der Medizin* 2020; 162:32-33Müssig K.
22. **Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.** *Obes Rev* 2020; Foldi M, Farkas N, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686331>
23. **Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.** *Obes Rev* 2020; Földi M, Farkas N, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686331>
24. **COVID-19 outbreak and pediatric diabetes: perceptions of health care professionals worldwide.** *Pediatr. Diabetes* 2020; Elbarbary NS, Dos Santos TJ, de Beaufort C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686287>
25. **COVID-19 Pandemic-Related Practices and Policies Affecting the Continuity of Behavioral Health Care Among Children With Diabetes.** *Transl. Behav. Med.* 2020; Clary L, Wang C, Byrne ME, Monaghan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710626>

Education and training and science (27 articles)

1. **Constraints Lead to Opportunities for Medical Education in Times of COVID-19 Pandemic.** *Acta Med Port* 2020; Ribeiro JC, Villanueva T, Gi A, Escada P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705979>
2. **Global surgery in the time of COVID-19: A trainee perspective.** *Am. J. Surg.* 2020; Ganguli S, Yibrehu B, Shah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684291>
3. **Research priorities for the COVID-19 pandemic and beyond: A call to action for psychological science.** *Br. J. Psychol.* 2020:e12468O'Connor DB, Aggleton JP, Chakrabarti B *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683689>
4. **Stress and anxiety among university students in France during Covid-19 mandatory confinement.** *Compr. Psychiatry* 2020; 102:152191 Husky MM, Kovess-Masfety V, Swendsen JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688023>
 5. **YouTube as a Source of Medical and Epidemiological Information During COVID-19 Pandemic: A Cross-Sectional Study of Content Across Six Languages Around the Globe.** *Cureus* 2020; 12:e8622 Dutta A, Beriwal N, Van Breugel LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685293>
 6. **The need to balance basic and clinical research with the safety of the research environment and personnel in the time of COVID-19 in the United States.** *Curr. Med. Res. Opin.* 2020:1 Tang Girdwood SC, Murphy M, Kaplan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696688>
 7. **Strategies to overcome limitations in Otolaryngology residency training during the COVID-19 pandemic.** *Eur Arch Otorhinolaryngol* 2020; Bandi F, Karligkiotis A, Mellia J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705361>
 8. **Factors Associated with the Perception of Risk and Knowledge of Contracting the SARS-Cov-2 among Adults in Bangladesh: Analysis of Online Surveys.** *Int J Environ Res Public Health* 2020; 17:Abir T, Kalimullah NA, Osuagwu UL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708161>
 9. **The impact of COVID-19 on global disparities in surgical training in pediatric otolaryngology.** *Int J Pediatr Otorhinolaryngol* 2020; 138:110267 Munjal T, Kavanagh KR, Ezzibdeh RM, Valdez TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705990>
 10. **Impact of the COVID-19 pandemic on orthopaedic and trauma surgery training in Europe.** *Int. Orthop.* 2020; Megaloi konomos PD, Thaler M, Igoumenou VG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696334>
 11. **An analysis of YouTube videos as educational resources for dental practitioners to prevent the spread of COVID-19.** *Ir. J. Med. Sci.* 2020; Yüce M, Adalı E, Kanmaz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700083>
 12. **Approaching the dermatology residency application process during a pandemic.** *J Am Acad Dermatol* 2020; Rosman IS, Schadt CR, Samimi SS, Rosenbach M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702459>
 13. **Protecting higher education institutions from COVID-19: insights from an Italian experience.** *J. Am. Coll. Health* 2020:1-2 Quattrone F, Borghini A, Emdin M, Nuti S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701399>
 14. **An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.** *J Infect Public Health* 2020; Wang D, Li Z, Liu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684351>
 15. **Perspectives From Rising Fourth Year Medical Students Regarding Strategies to Counteract the Effects of COVID-19 on Medical Education.** *J Med Educ Curric Dev* 2020; 7:2382120520940659 Liesman DR, Pumiglia L, Kemp MT, Alam HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704544>
 16. **The Potential Impact of COVID-19 on the Medical School Application.** *J Med Educ Curric Dev* 2020; 7:2382120520940666 O'Connell RL, Kemp MT, Alam HB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685689>
 17. **Breaking Bad News Training in the COVID-19 Era and Beyond.** *J Med Educ Curric Dev* 2020; 7:2382120520938706 Soosaipillai G, Archer S, Ashrafian H, Darzi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699822>
 18. **Impact of COVID-19 on academic activities and way forward in Indian Optometry.** *J Optom* 2020; Rajhans V, Memon U, Patil V, Goyal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703749>
 19. **Strengthening health care research and academics during and after COVID19 pandemic- an Indian perspective.** *J Oral Biol Craniofac Res* 2020; 10:343-346 Chowdhry A, Kapoor P, Popli DB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704469>
 20. **Academic clinical learning environment in obstetrics and gynecology during the COVID-19 pandemic: responses and lessons learned.** *J. Perinat. Med.* 2020; Olson HL, Townner D, Hiraoka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692706>
 21. **Disruption to Surgical Training during Covid-19 in the United States, United Kingdom, Canada, and Australasia: A Rapid Review of Impact and Mitigation Efforts.** *J Surg Educ* 2020; James HK, Pattison GTR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694085>
 22. **Rapid Adaptation of a Surgical Research Unit to Conduct Clinical Trials During the COVID-19 Pandemic.** *J. Surg. Res.* 2020; 256:76-82 Emamaullee J, Bowdish M, Yan PY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683060>
 23. **Sustainable Medical Teaching and Learning During the COVID-19 Pandemic: Surviving the New Normal.** *Malays. J. Med. Sci.* 2020; 27:137-142 Yusoff MSB, Hadie SNH, Mohamad I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684814>
 24. **Effect of the COVID-19 pandemic on medical student career perceptions: a national survey study.** *Med. Educ. Online* 2020; 25:1798088 Byrnes YM, Civantos AM, Go BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706306>
 25. **The impact and reach of the MJA in a year of living dangerously.** *Med. J. Aust.* 2020; 213:70-71 Talley Ac NJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683759>
 26. **Investing in Operational Research Capacity Building for Front-Line Health Workers Strengthens Countries' Resilience to Tackling the COVID-19 Pandemic.** *Trop Med Infect Dis* 2020; 5 Zachariah R, Dar Berger S, Thekkur P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708821>
 27. **By the Numbers Analysis of COVID-19's Effect on a Neurosurgical Residency at the Epicenter.** *World Neurosurg* 2020; Rothrock RJ, Maragkos GA, Schupper AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688039>

Elderly (18 articles)

1. **Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions.** *Acta Med Port* 2020; Laires PA, Nunes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707029>
2. **COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants.** *Aging Clin. Exp. Res.* 2020; Woolford SJ, D'Angelo S, Curtis EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705587>

3. **Grief and the COVID-19 Pandemic in Older Adults.** *Am J Geriatr Psychiatry* 2020; Goveas JS, Shear MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709542>
4. **Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study.** *Am J Geriatr Psychiatry* 2020; Hamm ME, Brown PJ, Karp JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682619>
5. **Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China.** *Arch Gerontol Geriatr* 2020; 91:104185Li T, Lu L, Zhang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688107>
6. **Lessons from Mass-Testing for COVID-19 in Long Term Care Facilities for the Elderly in San Francisco.** *Clin Infect Dis* 2020; Louie JK, Scott HM, DuBois A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687150>
7. **The key role of zinc in elderly immunity: A possible approach in the COVID-19 crisis.** *Clin Nutr ESPEN* 2020; 38:65-66de Almeida Brasiel PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690179>
8. **Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people.** *Eur Geriatr Med* 2020; Miles A, Webb TE, McLoughlin BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683576>
9. **Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York.** *Geriatr Gerontol Int* 2020; 20:732-734Miyashita S, Yamada T, Mikami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691924>
10. **Rural America's Hospitals are Not Prepared to Protect Older Adults From a Surge in COVID-19 Cases.** *Gerontol Geriatr Med* 2020; 6:2333721420936168Davoodi NM, Healy M, Goldberg EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685610>
11. **Prisons and COVID-19: A Desperate Call for Gerontological Expertise in Correctional Healthcare.** *Gerontologist* 2020; Prost SG, Novisky MA, Rorvig L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706885>
12. **Risk Interactions of Coronavirus Infection across Age Groups after the Peak of COVID-19 Epidemic.** *Int J Environ Res Public Health* 2020; 17Yu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708118>
13. **Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the Coronavirus Disease 2019 Pandemic.** *J Adolesc Health* 2020; Langmaid L, Ratner L, Huysman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684437>
14. **Older Adults' Intention to Socially Isolate Once COVID-19 Stay-at-Home Orders Are Replaced With "Safer-at-Home" Public Health Advisories: A Survey of Respondents in Maryland.** *J Appl Gerontol* 2020; 733464820944704Callow MA, Callow DD, Smith C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697126>
15. **Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.** *J Geriatr Oncol* 2020; Battisti NML, Mislav AR, Cooper L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709495>
16. **Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial study (COVID in Older PEople).** *J Hosp Infect* 2020; Carter B, Collins JT, Barlow-Pay F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702463>
17. **Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older.** *J Integr Med* 2020; Dang JZ, Zhu GY, Yang YJ, Zheng F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690444>
18. **Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters.** *Viruses* 2020; 12Osterrieder N, Bertzbach LD, Dietert K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698441>

Epidemiology 81 articles)

1. **Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions.** *Acta Med Port* 2020; Laires PA, Nunes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707029>
2. **The catch-22 of the COVID-19 "lockdown".** *Adv Respir Med* 2020; 88:285-286Malhotra N, Kunal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706114>
3. **Stopping the SARS-CoV-2 surge in the USA-CDC recommendations and ground realities.** *Adv Respir Med* 2020; 88:173-175Singh H, Popli T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706099>
4. **COVID-19 crisis, safe reopening of simulation centres and the new normal: food for thought.** *Adv Simul (Lond)* 2020; 5:13Ingrassia PL, Capogna G, Diaz-Navarro C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690997>
5. **Multivariate Analysis of Black Race and Environmental Temperature on COVID-19 in the US.** *Am J Med Sci* 2020; Li AY, Hannah TC, Durbin JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709397>
6. **Lessons Learned and Experiences Shared From the Front Lines: United Kingdom.** *Am Surg* 2020; 86:585-590Wexner SD, Cortés-Guiral D, Mortensen N, Darzi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683963>
7. **Changes in the spatial distribution of COVID-19 incidence in Italy using GIS-based maps.** *Ann Clin Microbiol Antimicrob* 2020; 19:30Martellucci CA, Sah R, Rabaan AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682420>
8. **Lessons learned: Commentary on patient harm related to COVID-19 prevention policies at a rural academic tertiary care facility.** *Ann Med Surg (Lond)* 2020; 57:20-21Mittal A, Chapman KD, Forte M, Al-Jaroushi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690992>
9. **The significance of case detection ratios for predictions on the outcome of an epidemic - a message from mathematical modelers.** *Arch Public Health* 2020; 78:63Fuhrmann J, Barbarossa MV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685147>
10. **Delaying the COVID-19 epidemic in Australia: evaluating the effectiveness of international travel bans.** *Aust N Z J Public Health* 2020; Adekunle A, Meehan M, Rojas-Alvarez D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697418>
11. **Basic epidemiological parameter values from data of real-world in mega-cities: the characteristics of COVID-19 in Beijing, China.** *BMC Infect Dis* 2020; 20:526Wang X, Pan Y, Zhang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689956>
12. **Simulating the effect of school closure during COVID-19 outbreaks in Ontario, Canada.** *BMC Med* 2020; 18:230Abdollahi E, Haworth-Brockman M, Keynan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698441>

- term=32709232
13. **SEIR model for COVID-19 dynamics incorporating the environment and social distancing.** *BMC Res. Notes* 2020; 13:352Mwalli S, Kimathi M, Ojiambo V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703315>
 14. **Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.** *Cell* 2020; Korber B, Fischer WM, Gnanakaran S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697968>
 15. **Mitigation of a COVID-19 Outbreak in a Nursing Home Through Serial Testing of Residents and Staff.** *Clin Infect Dis* 2020; Escobar DJ, Lanzi M, Saberi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687198>
 16. **Implications of test characteristics and population seroprevalence on 'immune passport' strategies.** *Clin Infect Dis* 2020; Larremore DB, Bubar KM, Grad YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687149>
 17. **Lessons from Mass-Testing for COVID-19 in Long Term Care Facilities for the Elderly in San Francisco.** *Clin Infect Dis* 2020; Louie JK, Scott HM, DuBois A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687150>
 18. **Low prevalence of active COVID-19 in Slovenia: a nationwide population study on a probability-based sample.** *Clin Microbiol Infect* 2020; Vodicar PM, Valencak AO, Zupan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688068>
 19. **Low prevalence of active COVID-19 in Slovenia: a nationwide population study on a probability-based sample.** *Clin Microbiol Infect* 2020; Vodičar PM, Valenčak AO, Zupan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688068>
 20. **Epidemiological and Clinical Features of SARS-CoV-2: A Retrospective Study from East Karachi, Pakistan.** *Cureus* 2020; 12:e8679Tahir S, Tahir SA, Bin Arif T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699679>
 21. **Data-driven modelling and prediction of COVID-19 infection in India and correlation analysis of the virus transmission with socio-economic factors.** *Diabetes Metab Syndr* 2020; 14:1231-1240Kumar A, Rani P, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683321>
 22. **Impact of Social Distancing Measures on Coronavirus Disease Healthcare Demand, Central Texas, USA.** *Emerg Infect Dis* 2020; 26Wang X, Pasco RF, Du Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692648>
 23. **The effect of latitude and PM2.5 on spreading of SARS-CoV-2 in tropical and temperate zone countries.** *Environ Pollut* 2020; 266:115176Chennakesavulu K, Reddy GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683090>
 24. **Epidemiological and clinical course of 483 patients with COVID-19 in Wuhan, China: a single-center, retrospective study from the mobile cabin hospital.** *Eur J Clin Microbiol Infect Dis* 2020; Wang B, Wang Z, Zhao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683596>
 25. **Italian Vò municipality cohort and COVID-19 epidemiology: The "Framingham" study of the 21(st) century.** *Eur J Intern Med* 2020; Zuin M, Bilato C, Zuliani G, Roncon L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709547>
 26. **SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.** *Euro Surveill* 2020; 25Fischer B, Knabbe C, Vollmer T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700672>
 27. **Prisons and COVID-19: A Desperate Call for Gerontological Expertise in Correctional Healthcare.** *Gerontologist* 2020; Prost SG, Novisky MA, Rorvig L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706885>
 28. **Factors Influencing Global Variations in COVID-19 Cases and Fatalities; A Review.** *Healthcare (Basel)* 2020; 8Abu Hammad O, Alnazzawi A, Borzangy SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708986>
 29. **Impact of COVID-19 Second Wave on Healthcare Workers Staffing Levels.** *Infect Control Hosp Epidemiol* 2020; 1-5Abuown A, Taube C, Koizia LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693865>
 30. **Bidirectional impact of imperfect mask use on reproduction number of COVID-19: A next generation matrix approach.** *Infect Dis Model* 2020; 5:405-408Fisman DN, Greer AL, Tuite AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691014>
 31. **Why lockdown? Why national unity? Why global solidarity? Simplified arithmetic tools for decision-makers, health professionals, journalists and the general public to explore containment options for the 2019 novel coronavirus.** *Infect Dis Model* 2020; 5:442-458Killeen GF, Kiware SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691016>
 32. **Mathematical modelling on phase based transmissibility of Coronavirus.** *Infect Dis Model* 2020; 5:375-385Krishna MV, Prakash J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695940>
 33. **Using statistics and mathematical modelling to understand infectious disease outbreaks: COVID-19 as an example.** *Infect Dis Model* 2020; 5:409-441Overton CE, Stage HB, Ahmad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691015>
 34. **Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.** *Infect Dis Poverty* 2020; 9:99Zhang XY, Huang HJ, Zhuang DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690096>
 35. **Factors Associated with the Perception of Risk and Knowledge of Contracting the SARS-Cov-2 among Adults in Bangladesh: Analysis of Online Surveys.** *Int J Environ Res Public Health* 2020; 17Abir T, Kalimullah NA, Osuagwu UL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708161>
 36. **Demographic and Comorbidities Data Description of Population in Mexico with SARS-CoV-2 Infected Patients(COVID19): An Online Tool Analysis.** *Int J Environ Res Public Health* 2020; 17Galván-Tejada CE, Zanella-Calzada LA, Villagrana-Bañuelos KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709027>
 37. **Moving Average Based Index for Judging the Peak of the COVID-19 Epidemic.** *Int J Environ Res Public Health* 2020; 17He Y, Wang X, He H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708007>
 38. **Would the United States Have Had Too Few Beds for Universal Emergency Care in the Event of a More Widespread Covid-19 Epidemic?** *Int J Environ Res Public Health* 2020; 17Jones RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707674>
 39. **A Clustering Approach to Classify Italian Regions and Provinces Based on Prevalence and Trend of SARS-CoV-2 Cases.** *Int J Environ Res Public Health* 2020; 17Maugeri A, Barchitta M, Agodi A.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707989>
40. **Why is Pakistan vulnerable to COVID-19 associated morbidity and mortality? A scoping review.** *Int J Health Plann. Manage.* 2020; Atif M, Malik I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700410>
 41. **Epidemiological and Clinical Characteristics of Coronavirus Disease 2019 in Daegu, South Korea.** *Int J Infect Dis* 2020; Lee JY, Hong SW, Hyun M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702415>
 42. **COVID-19 Pandemic in Nigeria: Palliative Measures and the Politics of Vulnerability.** *Int J MCH AIDS* 2020; 9:220-222Eranga IO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685279>
 43. **Estimation of the Hidden Population with COVID-19 Disease.** *Int J MCH AIDS* 2020; 9:217-219Soltanian AR, Bashirian S, Basti SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704408>
 44. **The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity?** *Int J Mol Sci* 2020; 21Holuka C, Merz MP, Fernandes SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707661>
 45. **What Does Adolescent Substance Use Look Like During the COVID-19 Pandemic? Examining Changes in Frequency, Social Contexts, and Pandemic-Related Predictors.** *J Adolesc. Health* 2020; Dumas TM, Ellis W, Litt DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693983>
 46. **Older Adults' Intention to Socially Isolate Once COVID-19 Stay-at-Home Orders Are Replaced With "Safer-at-Home" Public Health Advisories: A Survey of Respondents in Maryland.** *J. Appl. Gerontol.* 2020:733464820944704Callow MA, Callow DD, Smith C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697126>
 47. **Geographic components of SARS-CoV-2 expansion: a hypothesis.** *J Appl Physiol (1985)* 2020; Joyce KE, Weaver SR, Lucas SJE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702272>
 48. **Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: are we due for a second wave of COVID-19 in the fall?** *J Biol Regul Homeost Agents* 2020; 34Goren A, Wambier CG, McCoy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700513>
 49. **Lessons learnt from COVID 19: An Italian multicentric epidemiological study of orthopaedic and trauma services.** *J Clin Orthop Trauma* 2020; 11:721-727Giuntoli M, Bonicoli E, Bugelli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684717>
 50. **Lockdown is an effective 'vaccine' against COVID-19: A message from India.** *J Infect Dev Ctries* 2020; 14:545-546Krishan K, Kanchan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683342>
 51. **Global seasonality of human seasonal coronaviruses: a clue for post-pandemic circulating season of SARS-CoV-2 virus?** *J Infect Dis* 2020; Li Y, Wang X, Nair H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691843>
 52. **Unique challenges to control the spread of COVID-19 in the Middle East.** *J Infect Public Health* 2020; Baloch Z, Ma Z, Ji Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690454>
 53. **Outcomes of universal SARS-CoV-2 testing program in pregnant women admitted to hospital and the adjuvant role of lung ultrasound in screening: A prospective cohort study.** *J Matern Fetal Neonatal Med* 2020:1-22Yassa M, Yirmibes C, Cavusoglu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691641>
 54. **Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak.** *J R Soc Interface* 2020; 17:20200144Park SW, Bolker BM, Champredon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693748>
 55. **Geolocated Twitter social media data to describe the geographic spread of SARS-CoV-2.** *J Travel Med* 2020; Bisanzio D, Kraemer MUG, Brewer T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701135>
 56. **Serial Interval Distribution of SARS-CoV-2 Infection in Brazil.** *J Travel Med* 2020; Prete CA, Buss L, Dighe A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710618>
 57. **SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically Confirmed Cases.** *mSystems* 2020; 5Wu F, Zhang J, Xiao A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694130>
 58. **Willingness to Seek Diagnostic Testing for SARS-CoV-2 With Home, Drive-through, and Clinic-Based Specimen Collection Locations.** *Open Forum Infect Dis* 2020; 7:ofaa269Siegler AJ, Hall E, Luisi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704517>
 59. **European and United Kingdom COVID-19 pandemic experience: The same but different.** *Paediatr. Respir. Rev.* 2020; Carroll WD, Strenger V, Eber E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709461>
 60. **Consequences of physical distancing emanating from the COVID-19 pandemic: An Australian perspective.** *Paediatr. Respir. Rev.* 2020; Fitzgerald DA, Nunn K, Isaacs D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690355>
 61. **Role of modelling in COVID-19 policy development.** *Paediatr. Respir. Rev.* 2020; McBryde ES, Meehan MT, Adegboye OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690354>
 62. **What we may learn - and need - from pandemic fiction.** *Philos. Ethics Humanit. Med.* 2020; 15:4Doherty J, Giordano J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690053>
 63. **Why COVID-19 models should incorporate the network of social interactions.** *Phys. Biol.* 2020; Herrmann HA, Schwartz JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702678>
 64. **Screening testing for SARS-CoV-2 upon admission to rehabilitation hospitals in a high COVID-19 prevalence community.** *Pm r* 2020; Kirshblum SC, DeLauter G, Lopreiato MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700434>
 65. **COVID-19: Transmission in the incubation period.** *Pneumologie* 2020; 74:321-322Krome S.
 66. *Pneumologie* 2020; 74:315Schaberg T, Ewig S.
 67. **Modeling the effect of area deprivation on COVID-19 incidences: a study of Chennai megacity, India.** *Public Health* 2020; 185:266-269Das A, Ghosh S, Das K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707468>
 68. **Perfecting detection through education.** *Radiography (Lond)* 2020; Suleiman ME, Rickard M, Brennan PC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698948>
 69. **Evolution of effective serial interval of SARS-CoV-2 by non-pharmaceutical interventions.** *Res Sq* 2020; Ali ST, Wang L, Lau EHY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702717>
 70. **State-level impact of social distancing and testing on COVID-19 in the United States.** *Res Sq* 2020; Chiu WA, Fischer R, Ndeffo-Mbah ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702727>

71. **SARS-CoV-2 in the environment: Modes of transmission, early detection and potential role of pollutions.** *Sci Total Environ* 2020; 744:140946Al Huraimel K, Alhosani M, Kunhabdulla S, Stietiya MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687997>
72. **The spread of 2019-nCoV in China was primarily driven by population density. Comment on "Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China" by Zhu et al.** *Sci Total Environ* 2020; 744:141028Capiello S, Grillenzoni C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711328>
73. **Effect of meteorological parameters on spread of COVID-19 in India and air quality during lockdown.** *Sci Total Environ* 2020; 745:141021Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702548>
74. **Containing the spread of coronavirus disease 2019 (COVID-19): Meteorological factors and control strategies.** *Sci Total Environ* 2020; 744:140935Lin J, Huang W, Wen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688005>
75. **Effect of lockdown due to SARS COVID-19 on aerosol optical depth (AOD) over urban and mining regions in India.** *Sci Total Environ* 2020; 745:141024Ranjan AK, Patra AK, Gorai AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711073>
76. **Spatial and temporal differentiation of COVID-19 epidemic spread in mainland China and its influencing factors.** *Sci Total Environ* 2020; 744:140929Xie Z, Qin Y, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687995>
77. **Risk factors associated with occurrence of COVID-19 among household persons exposed to patients with confirmed COVID-19 in Qingdao Municipal, China.** *Transbound Emerg Dis* 2020; Xin H, Jiang F, Xue A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688447>
78. **COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey.** *Turk J Med Sci* 2020; Guner R, Hasanoglu I, Kayaaslan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682358>
79. **'Containment, delay, mitigation': waiting and care in the time of a pandemic.** *Wellcome Open Res* 2020; 5:129Baraitser L, Salisbury L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704549>
80. **Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China.** *Wellcome Open Res* 2020; 5:67Endo A, Abbott S, Kucharski AJ, Funk S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685698>
81. **The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019.** *Wellcome Open Res* 2020; 5:58Liu Y, Funk S, Flasche S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685697>

Management (64 articles)

1. **[Human Resources for Intensive Care Medicine in Portugal in the Post-COVID Era].** *Acta Med Port* 2020; Martins P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705980>
2. **Treatment of acute respiratory failure in the course of COVID-19. Practical hints from the expert panel of the Assembly of Intensive Care and Rehabilitation of the Polish Respiratory Society.** *Adv Respir Med* 2020; 88:245-266Czajkowska-Malinowska M, Kania A, Kuca PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706108>
3. **The authors' response: Propofol in COVID 19: From basic science to clinical impact.** *Am J Emerg Med* 2020; Soh M, Hifumi T, Isokawa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690223>
4. **Palliative Care During COVID-19: Data and Visits From Loved Ones.** *Am. J. Hosp. Palliat. Care* 2020;1049909120943577Heath L, Yates S, Carey M, Miller M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705889>
5. **The Coronavirus Pandemic: Experience From a Rural West Virginia Tertiary Care Hospital.** *Am. Surg.* 2020; 86:611-614Richmond BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683967>
6. **US Rural Surgeon Responses to the COVID-19 Pandemic: Leadership in a Time of Crisis.** *Am. Surg.* 2020; 86:602-610Sarap M, Conyers J, Cunningham C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683965>
7. **Lessons Learned and Experiences Shared From the Front Lines: United Kingdom.** *Am. Surg.* 2020; 86:585-590Wexner SD, Cortes-Guiral D, Mortensen N, Darzi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683963>
8. **Lessons Learned and Experiences Shared From the Front Lines: United Kingdom.** *Am. Surg.* 2020; 86:585-590Wexner SD, Cortés-Guiral D, Mortensen N, Darzi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683963>
9. **Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei.** *Ann Palliat Med* 2020; Chen Y, Zhang K, Zhu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692230>
10. **Clinical outcome of standardized oxygen therapy nursing strategy in COVID-19.** *Ann Palliat Med* 2020; Pan W, Li J, Ou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692228>
11. **American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.** *Arthritis Rheumatol* 2020; Wahezi DM, Lo MS, Rubinstein TB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705780>
12. **Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.** *Aust. Crit. Care* 2020; Chapple LS, Fetterplace K, Asrani V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682671>
13. **Opening Pandora's box: surgical tracheostomy in mechanically ventilated COVID-19 patients.** *Br J Anaesth* 2020; El-Wajeh Y, Varley I, Raithatha A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709307>
14. **Interdependence between elevated intra-abdominal, pleural, and airway opening pressure in severe acute respiratory distress syndrome with extracorporeal membrane oxygenation.** *Br J Anaesth* 2020; Mauri T, Spinelli E, Caccioppola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682550>
15. **THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.** *Br. J. Nutr.* 2020:1-37Florino S, Zippi M, Gallo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703328>
16. **The severe COVID-19: A sepsis induced by viral infection? and its immunomodulatory therapy.** *Chin. J. Traumatol.* 2020; Lin HY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690231>

17. **Micronutrients as immunomodulatory tools for COVID-19 management.** *Clin Immunol* 2020;108545Gasmi A, Tippairote T, Mujawdiya PK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710937>
18. **The syndrome of inappropriate antidiuresis in COVID-19 pneumonia: report of two cases.** *Clin Kidney J* 2020; 13:461-462Ravioli S, Niebuhr N, Ruchti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695328>
19. **The key role of zinc in elderly immunity: A possible approach in the COVID-19 crisis.** *Clin Nutr ESPEN* 2020; 38:65-66de Almeida Brasiel PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690179>
20. **Home medical nutrition during SARS-CoV-2 pandemic - A position paper.** *Clin Nutr ESPEN* 2020; 38:196-200Matras P, Klek S, Folwarski M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690158>
21. **Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.** *Crit Care* 2020; 24:454van Haren FMP, Page C, Laffey JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698853>
22. **Extracorporeal Membrane Oxygenation Support in a Young Patient With COVID-19 Infection.** *Cureus* 2020; 12:e8694Lima G, Cardoso E, Paredes MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699691>
23. **Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.** *Curr Med Chem* 2020; Laws M, Surani YM, Hasan MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693756>
24. **Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).** *Diabetes Metab Syndr* 2020; 14:1225-1229Subir R, Jagat JM, Kalyan KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683320>
25. **Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?** *Diabetes Metab Syndr* 2020; 14:1241-1242Wijaya I, Andhika R, Huang I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683322>
26. **Why change? Lessons in leadership from the COVID-19 pandemic.** *Eur J Cardiothorac Surg* 2020; Ahlsson A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688379>
27. **Integrative role of traditional and modern technologies to combat COVID-19.** *Expert Rev. Anti Infect. Ther.* 2020; Heiat M, Hashemi-Aghdam MR, Heiat F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703036>
28. **Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients.** *Expert Rev. Cardiovasc. Ther.* 2020; Kow CS, Thiruchelvam K, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700573>
29. **An integrated and intergenerational community response to promote holistic wellbeing during the COVID-19 pandemic.** *Explore (NY)* 2020; Bhagra O, Patel SR, Chon TY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690384>
30. **Better preventing and mitigating the effects of Covid-19.** *Future Sci OA* 2020; 6:Fso586Maguire G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685190>
31. **Preparing for COVID-19: The experiences of a long-term care facility in Taiwan.** *Geriatr Gerontol Int* 2020; 20:734-735Chen CR, Huang HC, Huang HC, Chen W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691923>
32. **Working Upstream in Advance Care Planning in Pandemic Palliative Care.** *Health Secur* 2020; Zaurova M, Krouss M, Israilov S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706629>
33. **Getting the COVID-19 pandemic into perspective: a nursing imperative.** *Int Nurs Rev* 2020; McDonald T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700379>
34. **Preparing for the SARS-CoV-2 pandemic: creation and implementation of new recommendations.** *J. Anesth.* 2020; Conrad D, Hoffmann P, Berwanger U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691227>
35. **Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain.** *J. Clin. Hypertens. (Greenwich)* 2020; Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710674>
36. **The effectiveness of supervisor support in lessening perceived uncertainties and emotional exhaustion of university employees during the COVID-19 crisis: the constraining role of organizational intrusiveness.** *J. Gen. Psychol.* 2020;1-20Charoensukmongkol P, Phungsoonthorn T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691689>
37. **A Case Report of Tracheostomy for a Patient with COVID-19: How to Minimize Medical Staff and Patient Risks.** *J Korean Med Sci* 2020; 35:e263Youn SH, Baek SY, Yoon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686375>
38. **How COVID-19 Is Testing and Evolving Our Communication Skills.** *J Med Imaging Radiat Sci* 2020; Julka-Anderson N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709543>
39. **Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.** *J Med Virol* 2020; Liu X, Liu Y, Chen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687223>
40. **Hemorrhagic stroke and anticoagulation in COVID-19.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104984Dogra S, Jain R, Cao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689588>
41. **Fibrinolysis and COVID-19: a tale of two sites?** *J Thromb Haemost* 2020; Keragala CB, Medcalf RL, Myles PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692877>
42. **The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience.** *J Thromb Haemost* 2020; Pesavento R, Ceccato D, Pasquetto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692874>
43. **Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.** *J. Thromb. Thrombolysis* 2020; Marchandot B, Trimaille A, Curtiaud A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696172>
44. **Impact of COVID-19 Within a Midwestern General Surgery Residency.** *Kans J Med* 2020; 13:194Brungardt JG, Schropp KP, Mammen JMV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695265>
45. **Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?** *mBio* 2020; 11Onishi JC, Häggblom MM, Shapses SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703911>
46. **First Nations peoples leading the way in COVID-19 pandemic planning, response and management.** *Med. J. Aust.* 2020; Crooks K, Casey D, Ward JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691433>
47. **Effect of Powered Air-Purifying Respirators on Speech Recognition Among Health Care Workers.** *Otolaryngol Head Neck Surg* 2020;194599820945685Kempfle JS, Panda A, Hottin M *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689877>
48. **Systems-Focused Simulation to Prepare for COVID-19 Intraoperative Emergencies.** *Paediatr Anaesth* 2020; Daly Guris RJ, Elliott EM, Doshi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683765>
 49. **Prone Positioning of Patients With Acute Respiratory Distress Syndrome Related to COVID-19: A Rehabilitation-Based Prone Team.** *Phys Ther* 2020; Ng JA, Miccile LA, Iracheta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691056>
 50. **Legal Issues of Resource Allocation in the COVID-19 Pandemic: Between Utilitarianism and Life Value Indifference.** *Pneumologie* 2020; 74:366-370Hübner J, Schewe DM, Katalinic A, Frielitz FS.
 51. **Use of External Ventilator Control Panel for Mechanical Ventilation in Patients with Severe SARS-CoV-2 Infection.** *QJM* 2020; Austin A, Pezzano C, Lydon D, Chopra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692813>
 52. **Antiviral anticoagulation.** *Res Pract Thromb Haemost* 2020; 4:774-788Pryzdial ELG, Sutherland MR, Lin BH, Horwitz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685886>
 53. **Respiratory support in patients with COVID-19 (outside intensive care unit). A position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases.** *Respir Med Res* 2020; 78:100768Rabec C, Gonzalez-Bermejo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707480>
 54. **Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy.** *Support Care Cancer* 2020; Faria KM, Gomes-Silva W, Kauark-Fontes E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696245>
 55. **SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer.** *Ther. Adv. Endocrinol. Metab.* 2020; 11:2042018820942385La Vignera S, Cannarella R, Condorelli RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699587>
 56. **Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide.** *Transpl Infect Dis* 2020:e13425Hu Q, Zhong Z, Xiong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702153>
 57. **Kidney Transplant Recipients Infected By COVID-19: Review of the Initial Published Experience.** *Transpl Infect Dis* 2020:e13426Moris D, Kesseli SJ, Barbas AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702150>
 58. **Influence of Immunosuppression on Seroconversion Against SARS-Cov-2 in Two Kidney Transplant Recipients.** *Transpl Infect Dis* 2020:e13423Wang AX, Quintero Cardona O, Ho DY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701196>
 59. **Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:666Daval M, Corré A, Palpacuer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690074>
 60. **Investing in Operational Research Capacity Building for Front-Line Health Workers Strengthens Countries' Resilience to Tackling the COVID-19 Pandemic.** *Trop Med Infect Dis* 2020; 5Zachariah R, Dar Berger S, Thekkur P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708821>
 61. **COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey.** *Turk J Med Sci* 2020; Güner R, Hasanoğlu İ, Kayaaslan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682358>
 62. **COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey.** *Turk J Med Sci* 2020; HR GU, Hasanoğlu I, Kayaaslan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682358>
 63. **The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.** *Turk J Med Sci* 2020; Tanriverdi E, ÇÖrtük M, Yildirim BZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682360>
 64. **Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden.** *Ups. J. Med. Sci.* 2020:1-6Lidstrom AK, Sund F, Albinsson B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3268411>

Mental – public health (39 articles)

1. **[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].** *Acta Med Port* 2020; Andrade G, Simões do Couto F, Câmara-Pestana L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705981>
2. **Grief and the COVID-19 Pandemic in Older Adults.** *Am J Geriatr Psychiatry* 2020; Goveas JS, Shear MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709542>
3. **Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study.** *Am J Geriatr Psychiatry* 2020; Hamm ME, Brown PJ, Karp JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682619>
4. **The neuropsychological impact of E-learning on children.** *Asian J Psychiatr* 2020; 54:102306Jha AK, Arora A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688279>
5. **Up-to-date review of psychotherapy via videoconference: implications and recommendations for the RANZCP Psychotherapy Written Case during the COVID-19 pandemic.** *Australas Psychiatry* 2020:1039856220939495Chherawala N, Gill S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689815>
6. **COVID-19 and Depressive Symptoms: A Community-based Study in Quebec, Canada.** *Can. J. Psychiatry* 2020:706743720943812Schmitz N, Holley P, Meng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700546>
7. **Sleep and circadian rhythm in response to the COVID-19 pandemic.** *Can. J. Public Health* 2020; Morin CM, Carrier J, Bastien C, Godbout R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700231>
8. **Stress and anxiety among university students in France during Covid-19 mandatory confinement.** *Compr. Psychiatry* 2020; 102:152191Husky MM, Kovess-Masfety V, Swendsen JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688023>
9. **Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York.** *Geriatr Gerontol Int* 2020; 20:732-734Miyashita S, Yamada T, Mikami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691924>

10. **China's model to combat the COVID-19 epidemic: a public health emergency governance approach.** *Glob Health Res Policy* 2020; 5:34Ning Y, Ren R, Nkengurutse G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685691>
11. **Engaging the communities in Wuhan, China during the COVID-19 outbreak.** *Glob Health Res Policy* 2020; 5:35Zhu J, Cai Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685692>
12. **The world expects effective global health interventions: Can global health deliver?** *Glob Public Health* 2020;1-8Holst J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684125>
13. **Eleven things not to say to healthcare professionals during the COVID-19 pandemic.** *Headache* 2020; Robblee J, Buse DC, Halker Singh RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696455>
14. **Combat Stress Management and Resilience: Adapting Department of Defense Combat Lessons Learned to Civilian Healthcare during the COVID-19 Pandemic.** *Health Secur* 2020; Wei EK, Segall J, Linn-Walton R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706595>
15. **Exploring COVID-19 stress and its factors in Bangladesh: A perception-based study.** *Heliyon* 2020; 6:e04399Islam SMD, Bodrud-Doza M, Khan RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685726>
16. **Physical and mental health impacts of COVID-19 on healthcare workers: a scoping review.** *Int. J. Emerg. Med.* 2020; 13:40Shaukat N, Ali DM, Razzak J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689925>
17. **Psychological Factors that Lessen the Impact of COVID-19 on the Self-Employment Intention of Business Administration and Economics' Students from Latin America.** *Int J Environ Res Public Health* 2020; 17Hernández-Sánchez BR, Cardella GM, Sánchez-García JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708034>
18. **Sleep Pattern Changes in Nursing Students during the COVID-19 Lockdown.** *Int J Environ Res Public Health* 2020; 17Romero-Blanco C, Rodríguez-Almagro J, Onieva-Zafra MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698343>
19. **Puppy love in the time of Corona: Dog ownership protects against loneliness for those living alone during the COVID-19 lockdown.** *Int J Soc Psychiatry* 2020;20764020944195Oliva JL, Johnston KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701015>
20. **Health Policy and Leadership Models During the COVID-19 Pandemic- Review Article.** *Int J Surg* 2020; Nicola M, Sohrabi C, Mathew G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687873>
21. **Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the Coronavirus Disease 2019 Pandemic.** *J. Adolesc. Health* 2020; Langmaid L, Ratner L, Huysman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684437>
22. **Panic and generalized anxiety during the COVID-19 pandemic among Bangladeshi people: An online pilot survey early in the outbreak.** *J. Affect. Disord.* 2020; 276:30-37Islam MS, Ferdous MZ, Potenza MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697713>
23. **An analysis on the panic during COVID-19 pandemic through an online form.** *J. Affect. Disord.* 2020; 276:14-22Nicomedes CJC, Avila RMA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697692>
24. **Mental health of healthcare workers during the COVID-19 pandemic in Italy.** *J. Eval. Clin. Pract.* 2020; Di Tella M, Romeo A, Benfante A, Castelli L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710481>
25. **Psychological Impact of Quarantine on Caregivers at a Children's Hospital for Contact with Case of COVID-19.** *J Korean Med Sci* 2020; 35:e255Kim H, Park KJ, Shin YW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686372>
26. **The psychosocial implications of COVID-19 for a neurology program in a pandemic epicenter.** *J Neurol Sci* 2020; 416:117034Croll L, Kurzweil A, Hasanaj L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683274>
27. **Mental health issues impacting pharmacists during COVID-19.** *J Pharm Policy Pract* 2020; 13:46Elbeddini A, Wen CX, Tayefehchamani Y, To A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704376>
28. **The role of spirituality in the COVID-19 pandemic: a spiritual hotline project.** *J Public Health (Oxf)* 2020; Ribeiro MRC, Damiano RF, Marujo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696967>
29. **Statewide Implementation of Virtual Perinatal Home Visiting During COVID-19.** *Matern Child Health J* 2020; Marshall J, Kihlström L, Buro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691359>
30. **The mortality and psychological burden caused by response to COVID-19 outbreak.** *Med. Hypotheses* 2020; 143:110069Yusuf E, Tisler A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688184>
31. **Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic.** *Mult Scler Relat Disord* 2020; 45:102380Radulovic L, Erakovic J, Roganovic M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683304>
32. **Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak.** *Mult Scler Relat Disord* 2020; 45:102407Stojanov A, Malobabic M, Milosevic V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702641>
33. **Psychological Aspects and Eating Habits during COVID-19 Home Confinement: Results of EHLC-COVID-19 Italian Online Survey.** *Nutrients* 2020; 12Di Renzo L, Gualtieri P, Cinelli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707724>
34. **Consequences of physical distancing emanating from the COVID-19 pandemic: An Australian perspective.** *Paediatr. Respir. Rev.* 2020; Fitzgerald DA, Nunn K, Isaacs D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690355>
35. **Psychological burden of quarantine in children and adolescents: A rapid systematic review and proposed solutions.** *Pak J Med Sci* 2020; 36:1106-1116Imran N, Aamer I, Sharif MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704298>
36. **Evaluation of psychological stress in scientific researchers during the 2019-2020 COVID-19 outbreak in China.** *PeerJ* 2020; 8:e9497Zhang X, Li X, Liao Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704451>
37. **Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China.** *Psychiatry Res* 2020; 292:113297Liu D, Baumeister RF, Veilleux JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707218>
38. **Not all worries were created equal: the case of COVID-19 anxiety.** *Public Health* 2020; 185:243-245Maaravi Y, Heller B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688099>
39. **Social, ethical and behavioural aspects of COVID-19.** *Wellcome Open Res* 2020; 5:90Pan-Ngum W, Poomchaichote T, Cuman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704548>

Meta-analyses - systematic reviews (10 articles)

1. **Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis.** *Can J Kidney Health Dis* 2020; 7:2054358120938573Lim MA, Pranata R, Huang I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685180>
2. **Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis.** *Crit Care* 2020; 24:459Chen XY, Huang MY, Xiao ZW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709251>
3. **Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis.** *Diabetes Res Clin Pract* 2020:108346Guo L, Shi Z, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710998>
4. **Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.** *EBioMedicine* 2020; 58:102916Weiss A, Jellingsø M, Sommer MOA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711256>
5. **Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis.** *Environ. Sci. Pollut. Res. Int.* 2020; Malik VS, Ravindra K, Attri SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710359>
6. **Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.** *Hepatol Int* 2020; Wu Y, Li H, Guo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710250>
7. **Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: a systematic review and meta-analysis.** *J Med Virol* 2020; Bwire GM, Majigo MV, Njiro BJ, Mawazo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706393>
8. **Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis.** *J Med Virol* 2020; Gao Y, Liu M, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687228>
9. **Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.** *J Med Virol* 2020; He J, Guo Y, Mao R, Zhang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691881>
10. **Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.** *Obes Rev* 2020; Foldi M, Farkas N, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686331>

Mortality (19 articles)

1. **Risk of death by age and gender from CoVID-19 in Peru, March-May, 2020.** *Aging (Albany NY)* 2020; 12Munayco C, Chowell G, Tariq A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692724>
2. **Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe.** *Cardiol Ther* 2020; Goel S, Jain T, Hooda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683639>
3. **Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: A case series.** *Case Rep Womens Health* 2020; 27:e00243Richtmann R, Torloni MR, Oyamada Otani AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704477>
4. **Alteration of serum markers in COVID-19 and implications on mortality.** *Clin Transl Med* 2020:e119Liu D, Li R, Yu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696591>
5. **Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis.** *Diabetes Res Clin Pract* 2020:108346Guo L, Shi Z, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710998>
6. **Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.** *Eur. J. Haematol.* 2020; Sanchez-Pina JM, Rodríguez Rodríguez M, Castro Quismondo N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710500>
7. **All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England.** *Euro Surveill* 2020; 25Sinnathamby MA, Whitaker H, Coughlan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700669>
8. **Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.** *Haematologica* 2020; Perotti C, Baldanti F, Bruno R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703797>
9. **Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain.** *Int J Environ Res Public Health* 2020; 17Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709002>
10. **Worldwide maternal deaths due to COVID-19: A brief review.** *Int J Gynaecol Obstet* 2020; Nakamura-Pereira M, Andreucci CB, de Oliveira Menezes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706925>
11. **Why is Pakistan vulnerable to COVID-19 associated morbidity and mortality? A scoping review.** *Int. J. Health Plann. Manage.* 2020; Atif M, Malik I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700410>
12. **Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants.** *Int J Infect Dis* 2020; de Sousa E, Ligeiro D, Lérias JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693089>
13. **Role of neutrophil-lymphocyte-ratio in the mortality of males diagnosed with COVID-19.** *Iran J Microbiol* 2020; 12:194-197Belice T, Demir I, Yüksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685114>
14. **Interleukin-6-based mortality risk model for hospitalised COVID-19 patients.** *J Allergy Clin Immunol* 2020; Rocio LG, Alberto UR, Paloma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710975>
15. **The mortality and psychological burden caused by response to COVID-19 outbreak.** *Med. Hypotheses* 2020; 143:110069Yusuf E, Tisler A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688184>
16. **Selenium Deficiency Is Associated with Mortality Risk from COVID-19.** *Nutrients* 2020; 12Moghaddam A, Heller RA, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708526>

17. **No clear association emerges between intergenerational relationships and COVID-19 fatality rates from macro-level analyses.** *Proc Natl Acad Sci U S A* 2020; Arpino B, Bordone V, Pasqualini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699150>
18. **Coronavirus disease 2019 mortality: a multivariate ecological analysis in relation to ethnicity, population density, obesity, deprivation and pollution.** *Public Health* 2020; 185:261-263 Bray I, Gibson A, White J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693249>
19. **[Using Markov Chain Monte Carlo methods to estimate the age-specific case fatality rate of COVID-19].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E076 Du ZC, Hao YT, Wei YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683819>

Online – IT – Apps (32 articles)

1. **Telecardiology during the Covid-19 pandemic: past mistakes and future hopes.** *Am. J. Cardiovasc. Dis.* 2020; 10:34-47 De Simone V, Guarise P, Guardalben S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685262>
2. **Up-to-date review of psychotherapy via videoconference: implications and recommendations for the RANZCP Psychotherapy Written Case during the COVID-19 pandemic.** *Australas Psychiatry* 2020; 1039856220939495 Chherawala N, Gill S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689815>
3. **HRS/EHRA/APHS/LAHR/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic.** *Circ Arrhythm Electrophysiol* 2020; 13:e009007 Varma N, Marrouche NF, Aguinaga L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692972>
4. **YouTube as a Source of Medical and Epidemiological Information During COVID-19 Pandemic: A Cross-Sectional Study of Content Across Six Languages Around the Globe.** *Cureus* 2020; 12:e8622 Dutta A, Beriwal N, Van Breugel LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685293>
5. **Remote Assessment of Video-Recorded Oral Presentations Centered on a Virtual Case-Based Module: A COVID-19 Feasibility Study.** *Cureus* 2020; 12:e8726 Krawiec C, Myers A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699721>
6. **Teledermatology with general practitioners and paediatricians during COVID-19 outbreak in Italy: preliminary data from a second level dermatology department in North-Eastern Italy.** *Dermatol Ther* 2020; e14040 Bergamo S, Calacione R, Fagotti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696492>
7. **Will "Video kill the Radiostar" or is zooming just a pandemic transient Hype? Some cautionary notes.** *Dig. Liver Dis.* 2020; Macedo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703728>
8. **From community-acquired pneumonia to COVID-19: a deep learning-based method for quantitative analysis of COVID-19 on thick-section CT scans.** *Eur Radiol* 2020; Li Z, Zhong Z, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683550>
9. **YouTube coverage of COVID-19 vaccine development: implications for awareness and uptake.** *Hum Vaccin Immunother* 2020; 1-4 Basch CH, Hillyer GC, Zagnit EA, Basch CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701403>
10. **Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases.** *Hum Vaccin Immunother* 2020; 1-8 Puri N, Coomes EA, Haghbayan H, Gunaratne K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693678>
11. **Factors Associated with the Perception of Risk and Knowledge of Contracting the SARS-Cov-2 among Adults in Bangladesh: Analysis of Online Surveys.** *Int J Environ Res Public Health* 2020; 17 Abir T, Kalimullah NA, Osuagwu UL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708161>
12. **Demographic and Comorbidities Data Description of Population in Mexico with SARS-CoV-2 Infected Patients (COVID19): An Online Tool Analysis.** *Int J Environ Res Public Health* 2020; 17 Galván-Tejada CE, Zanella-Calzada LA, Villagrana-Bañuelos KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709027>
13. **Social Networks' Engagement During the COVID-19 Pandemic in Spain: Health Media vs. Healthcare Professionals.** *Int J Environ Res Public Health* 2020; 17 Pérez-Escoda A, Jiménez-Narros C, Perlado-Lamo-de-Espinosa M, Pedrero-Esteban LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708231>
14. **An analysis of YouTube videos as educational resources for dental practitioners to prevent the spread of COVID-19.** *Ir. J. Med. Sci.* 2020; Yüce M, Adalı E, Kanmaz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700083>
15. **Panic and generalized anxiety during the COVID-19 pandemic among Bangladeshi people: An online pilot survey early in the outbreak.** *J. Affect. Disord.* 2020; 276:30-37 Islam MS, Ferdous MZ, Potenza MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697713>
16. **An analysis on the panic during COVID-19 pandemic through an online form.** *J. Affect. Disord.* 2020; 276:14-22 Nicomedes CJC, Avila RMA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697692>
17. **Google search increase in patient self-care during COVID-19 lockdown.** *J Am Acad Dermatol* 2020; Searle T, Al-Niaimi F, Ali FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707255>
18. **Rapid design and deployment of intensive outpatient group-based psychiatric care using telehealth during COVID-19.** *J Am Med Inform Assoc* 2020; Childs AW, Unger A, Li L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687151>
19. **A Model for Rapid Transition to Virtual Care, VA Connecticut Primary Care Response to COVID-19.** *J Gen Intern Med* 2020; Spelman JF, Brienza R, Walsh RF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705471>
20. **Feasibility and safety of urgently initiated maternal telemedicine in response to the spread of COVID-19: A 1-month report.** *J. Obstet. Gynaecol. Res.* 2020; Nakagawa K, Umazume T, Mayama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691488>
21. **Telehealth during the coronavirus disease 2019 pandemic: Rapid expansion of telehealth outpatient use during a pandemic is possible if the programme is previously established.** *J Telemed Telecare* 2020; 1357633x20942045 Schulz T, Long K, Kanhutu K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686556>
22. **Scaling virtual health at the epicentre of coronavirus disease 2019: A case study from NYU Langone Health.** *J Telemed Telecare* 2020; 1357633x20941395 Sherwin J, Lawrence K, Gragnano V, Testa PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686555>

23. **Geolocated Twitter social media data to describe the geographic spread of SARS-CoV-2.** *J Travel Med* 2020; Bisanzio D, Kraemer MUG, Brewer T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701135>
24. **COVID-19 in MS and NMO: A multicentric online national survey in Chile.** *Mult Scler Relat Disord* 2020; 45:102392 Ciampi E, Uribe-San-Martin R, Soler B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683306>
25. **Telemedicine in Neurosurgery: Lessons Learned from a Systematic Review of the Literature for the COVID-19 Era and Beyond.** *Neurosurgery* 2020; Eichberg DG, Basil GW, Di L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687191>
26. **Hospital Emergency Management of Emerging Infectious Disease using Instant Communication Technology - ERRATUM.** *Prehosp. Disaster Med.* 2020; 35:473 Lin CH, Hsieh CC, Chi CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690128>
27. **Staying updated on COVID-19: Social media to amplify science in thrombosis and hemostasis.** *Res Pract Thromb Haemost* 2020; 4:722-726 Makris M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685878>
28. **When the fourth water and digital revolution encountered COVID-19.** *Sci Total Environ* 2020; 744:140980 Poch M, Garrido-Baserba M, Corominas L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687996>
29. **On the efficacy of online drug surveys during the time of COVID-19.** *Subst. Abuse* 2020; 41:283-285 Palamar JJ, Acosta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697173>
30. **Rapid Decline in Telestroke Consults in the Setting of COVID-19.** *Telemed J E Health* 2020; Shah SO, Dharia R, Stazi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706615>
31. **Monitoring online media reports for early detection of unknown diseases: insight from a retrospective study of COVID-19 emergence.** *Transbound Emerg Dis* 2020; Valentin S, Mercier A, Lancelot R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683774>
32. **Deploying Machine and Deep Learning Models for Efficient Data-Augmented Detection of COVID-19 Infections.** *Viruses* 2020; 12 Sedik A, Iliyasu AM, Abd El-Rahiem B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708803>

Other – Miscellaneous (35 articles)

1. **Adolescent driving behavior before and during restrictions related to COVID-19.** *Accid. Anal. Prev.* 2020; 144:105686 Stavrinou D, McManus B, Mrug S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683132>
2. **Coronavirus disease 2019: What could be the effects on Road safety?** *Accid. Anal. Prev.* 2020; 144:105687 Vingilis E, Beirness D, Boase P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683133>
3. **[Reply to a Comment Published on Acta Med Port 2020; May 25; doi:10.20344/amp.14155 about the Article Published on Acta Med Port 2020; Apr 27; doi:10.20344/amp.13928].** *Acta Med Port* 2020; Nogueira PJ, De Araújo Nobre M, Nicola PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691722>
4. **Alcohol Intake in Attempt to Fight COVID-19: A Medical Myth in Iran.** *Alcohol* 2020; Aghababaeian H, Hamdanieh L, Ostadtaghizadeh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693023>
5. **Advocacy during crisis: Maintaining a legislative presence during the COVID-19 pandemic.** *Am. J. Health Syst. Pharm.* 2020; Berger K, Stephen Kaplan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702752>
6. **Ethical Responses to a Pandemic: Implications for the Ethos and Practice of Anatomy as a Health Science Discipline.** *Anat Sci Educ* 2020; Jones DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705774>
7. **A Dangerous "Cocktail": The COVID-19 Pandemic and the Youth Opioid Crisis in North America: A Response to Vigo et al. (2020).** *Can. J. Psychiatry.* 2020;706743720943820 Jayasinha R, Nairn S, Conrod P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701377>
8. **Extraordinary times call for extraordinary measures: the use of music to communicate public health recommendations against the spread of COVID-19.** *Can. J. Public Health.* 2020; Cournoyer Lemaire E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696141>
9. **A special thank you to our authors for their responses to the coronavirus disease pandemic.** *Cjem* 2020; 22:399 Stiell IG, Atkinson P, Lang E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697182>
10. **A Case Study: Analysis of Patents of Coronaviruses and Covid-19 for Technology Assessment and Future Research.** *Curr. Pharm. Des.* 2020; Musyuni P, Aggarwal G, Nagpal M, Goyal RK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693757>
11. **Fierce Advocates for Building All-Hazards Resurgence and Resilience: NYC Health + Hospitals' COVID-19 Experiences Applied.** *Health Secur* 2020; Cagliuso Nv, Sr., McGinty M, Madad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706596>
12. **Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2.** *Immunology* 2020; Novak N, Cabanillas B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687609>
13. **Rethinking Air Quality and Climate Change after COVID-19.** *Int J Environ Res Public Health* 2020; 17 Ching J, Kajino M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708953>
14. **Decrease in Ambient Fine Particulate Matter during COVID-19 Crisis and Corresponding Health Benefits in Seoul, Korea.** *Int J Environ Res Public Health* 2020; 17 Han C, Hong YC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707971>
15. **Physical Activity, Screen Time, and Emotional Well-Being during the 2019 Novel Coronavirus Outbreak in China.** *Int J Environ Res Public Health* 2020; 17 Qin F, Song Y, Nassiss GP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709003>
16. **COVID-19 - An Opportunity to Redesign Health Policy Thinking.** *Int J Health Policy Manag* 2020; Sturmberg JP, Tzasis P, Hoemeke L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702802>
17. **The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity?** *Int J Mol Sci* 2020; 21 Holuka C, Merz MP, Fernandes SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707661>
18. **Word War III.** *Int J Occup Environ Med* 2020; 11:117-118 Habibzadeh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683423>
19. **Medical professionalism in times of COVID-19 pandemic: is economic logic trumping medical ethics?** *Intern Emerg Med* 2020; Curkovic M, Kosec A, Curkovic D. <http://www.ncbi.nlm.nih.gov/pubmed/>

- term=32686058
20. **Medical professionalism in times of COVID-19 pandemic: is economic logic trumping medical ethics?** Intern Emerg Med 2020; Ćurković M, Košec A, Ćurković D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686058>
 21. **Rostrum: Managing Food Allergy in Schools During the COVID-19 Pandemic.** J Allergy Clin Immunol Pract 2020; Greenhawt M, Shaker M, Stukus DR *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711118>
 22. **Consensus on Recommendations for Safe Sexual Activity during the COVID-19 Coronavirus Pandemic.** J Clin Med 2020; 9Cabello F, Sánchez F, Farré JM, Montejo AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698369>
 23. **Ambient Air Pollution, Meteorology, and COVID-19 Infection in Korea.** J Med Virol 2020; Hoang T, Thi Anh TT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691877>
 24. **Alcohol advertisers may be using social media to encourage parents to drink during COVID-19.** Med. J. Aust. 2020; Leung J, Connor J, Hides L, Hall WD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683705>
 25. **Covid-19 and medical negligence litigation: Immunity for healthcare professionals?** Med. Leg. J. 2020:25817220935892Duignan K, Bradbury C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700595>
 26. **Psychological Aspects and Eating Habits during COVID-19 Home Confinement: Results of EHLCOVID-19 Italian Online Survey.** Nutrients 2020; 12Di Renzo L, Gualtieri P, Cinelli G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707724>
 27. **Legal Issues of Resource Allocation in the COVID-19 Pandemic: Between Utilitarianism and Life Value Indifference.** Pneumologie 2020; 74:366-370Hübner J, Schewe DM, Katalinic A, Frielitz FS.
 28. **Meditations on Involuntary Civil Commitment Amid a Pandemic.** Psychiatr. Serv. 2020:appips71901Barnett B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703118>
 29. **Effect of meteorological parameters on spread of COVID-19 in India and air quality during lockdown.** Sci Total Environ 2020; 745:141021Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702548>
 30. **When the fourth water and digital revolution encountered COVID-19.** Sci Total Environ 2020; 744:140980Poch M, Garrido-Baserba M, Corominas L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687996>
 31. **COVID-19 and the environment: A critical review and research agenda.** Sci Total Environ 2020; 745:141022Shakil MH, Munim ZH, Tasnia M, Sarowar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711074>
 32. **Reductions in mortality resulting from reduced air pollution levels due to COVID-19 mitigation measures.** Sci Total Environ 2020; 744:141012Son JY, Fong KC, Heo S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693269>
 33. **Environmental side effects of the injudicious use of antimicrobials in the era of COVID-19.** Sci Total Environ 2020; 745:141053Usman M, Farooq M, Hanna K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702547>
 34. **Effects of oral care on prolonged viral shedding in coronavirus disease 2019 (COVID-19).** Spec. Care Dentist 2020; Warabi Y, Tobisawa S, Kawazoe T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706510>
 35. **COVID-19-like symptoms observed in the Chinese tree shrews infected with SARS-CoV-2.** Zool Res 2020:1-5Xu L, Yu DD, Ma YH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701249>

Pathology (6 articles)

1. **The role of breast FNA during and post- COVID-19 pandemic: a fast and safe alternative to needle core biopsy.** Cytopathology 2020; Pinto D, Schmitt F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705731>
2. **COVID 19: Autopsy study confirms lung damage and risk of thromboembolism.** Deutsche Medizinische Wochenschrift 2020; 145:807-808Krome S.
3. **Third Trimester Placentas of SARS-CoV-2-Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization.** Histopathology 2020; Smithgall MC, Liu-Jarin X, Hamele-Bena D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692408>
4. **COVID-19 and cryo-EM.** IUCrJ 2020; 7:575-576Subramaniam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695405>
5. **The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections.** J. Neuroimmune Pharmacol. 2020; Machhi J, Herskovitz J, Senan AM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696264>
6. **Autopsy of patients with COVID-19: A balance of fear and curiosity.** Pathol. Res. Pract. 2020; 216:153039Hirschbühl K, Schaller T, Kling E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703502>

Protection (46 articles)

1. **Chest Radiographs and CTs in the Era of COVID-19: Indications, Operational Safety Considerations and Alternative Imaging Practices.** Acad Radiol 2020; Chia AQX, Cheng LT, Wijaya L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703648>
2. **Environmental maintenance with effective and useful zoning to protect patients and medical staff from COVID-19 infection.** Acute Med Surg 2020; 7:e536Ogawa F, Kato H, Sakai K *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685174>
3. **"Palliative Pandemic Plan," Triage and Symptoms Algorithm as a Strategy to Decrease Providers' Exposure, While Trying to Increase Teams Availability and Guidance for Goals of Care (GOC) and Symptoms Control.** Am. J. Hosp. Palliat. Care 2020:1049909120942494Lopez S, Decastro G, Van Ogtrop KM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691604>
4. **Practice and exploration of infection prevention and control measures based on risk management of surgical patients during the epidemic of Corona Virus Disease 2019 (COVID-19).** Am. J. Infect. Control 2020; Ren Y, Liu S, Yang L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702389>

5. **Improving protection from bioaerosol exposure during postoperative patient interaction in the COVID-19 era, a quality improvement study.** *Am. J. Otolaryngol.* 2020; 41:102634Ko-Keeney EH, Saran MS, McLaughlin K, Lipman S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707426>
6. **Surgical Masks During the Influenza Pandemic of 1918-1920.** *Am. Surg.* 2020; 86:557-559Nakayama DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683953>
7. **The design and manufacture of 3D-printed adjuncts for powered air-purifying respirators.** *Anaesth Rep* 2020; 8:e12055Miles LF, Chuen J, Edwards L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705085>
8. **How to Leverage Collaborations Between the BME Community and Local Hospitals to Address Critical Personal Protective Equipment Shortages During the COVID-19 Pandemic.** *Ann. Biomed. Eng.* 2020; George MP, Maier LA, Kasperbauer S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710248>
9. **Prevalence of positive COVID-19 among asymptomatic health care workers who care patients infected with the novel coronavirus: A retrospective study.** *Ann Med Surg (Lond)* 2020; 57:14-16Al-Zoubi NA, Obeidat BR, Al-Ghazo MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690991>
10. **Probability of fit failure with reuse of N95 mask respirators.** *Br J Anaesth* 2020; Maranhao B, Scott AW, Scott AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682553>
11. **Operational considerations for peritoneal dialysis management during the COVID-19 pandemic.** *Clin Kidney J* 2020; 13:322-327Yang Z, Dong J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695321>
12. **Gas Leaks Through Laparoscopic Energy Devices and Robotic Instrumentation-Video Vignette.** *Colorectal Dis* 2020; Dalli J, Faraz Khan M, Nolan K, Cahill RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691961>
13. **Enteral stoma care during COVID-19 pandemic: practical advice.** *Colorectal Dis* 2020; Pata F, Bondurri A, Ferrara F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691949>
14. **Perceived Risk, Behavior Changes and Health-related Outcomes During COVID-19 Pandemic: Findings among Adults with and without Diabetes in China.** *Diabetes Res Clin Pract* 2020:108350Yan AF, Sun X, Zheng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710996>
15. **Endoscopic mask innovation and protective measures changes during the COVID-19 pandemic: experience from a Chinese hepato-biliary-pancreatic unit.** *Dig. Endosc* 2020; Tian Q, Yan X, Shi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702176>
16. **Collection and disinfection of forensic biological specimens in five cases concerning COVID-19 in Guangzhou, China.** *Forensic Sci. Int.* 2020; 2:210-214Yang X, Xu Q, Liu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705079>
17. **The role of isolation rooms, facemasks and intensified hand hygiene in the prevention of nosocomial COVID-19 transmission in a pulmonary clinical setting.** *Infect Dis Poverty* 2020; 9:104Zhang GQ, Pan HQ, Hu XX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703281>
18. **Risk Interactions of Coronavirus Infection across Age Groups after the Peak of COVID-19 Epidemic.** *Int J Environ Res Public Health* 2020; 17Yu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708118>
19. **Standard precaution measurements during ophthalmology practice in the pandemic stage of COVID-19.** *Int J Ophthalmol* 2020; 13:1017-1022Reda AM, Ahmed WM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685386>
20. **Nurses' health beliefs about paper face masks in Japan, Australia and China: a qualitative descriptive study.** *Int Nurs Rev* 2020; Omura M, Stone TE, Petrini MA, Cao R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686094>
21. **Surgical pearl: Novel techniques of wearing ear-looped mask for reducing pressure on the ear.** *J Am Acad Dermatol* 2020; Mukhtar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702460>
22. **Application of hydrogel patches to the upper margins of N95 respirators as a novel anti-fog measure for goggles: a prospective, self-controlled study.** *J Am Acad Dermatol* 2020; Zhou N, Suo H, Alamgir M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692998>
23. **Protecting higher education institutions from COVID-19: insights from an Italian experience.** *J. Am. Coll. Health* 2020:1-2Quattrone F, Borghini A, Emdin M, Nuti S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701399>
24. **Reducing risky behavior with habit reversal: A review of behavioral strategies to reduce habitual hand-to-head behavior.** *J. Appl. Behav. Anal.* 2020; Heinicke MR, Stiede JT, Miltenberger RG, Woods DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686131>
25. **Optimal control strategies for the transmission risk of COVID-19.** *J. Biol. Dyn.* 2020; 14:590-607Lemecha Obsu L, Feyissa Balcha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696723>
26. **Acquired infection after intubating patients with COVID-19: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 67:110006Zhang J, Sun M, Li N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711351>
27. **Risk for dental healthcare professionals during the COVID-19 global pandemic: an evidence-based assessment.** *J. Dent.* 2020:103434Ren Y, Feng C, Rasubala L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693111>
28. **SARS-CoV-2 infection among healthcare workers in a hospital in Madrid, Spain.** *J Hosp Infect* 2020; García IS, López M, Vicente AS, Abascal PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702465>
29. **Mass masking as a way to contain COVID-19 and exit lockdown in low- and middle-income countries.** *J Infect* 2020; Fodjo JNS, Pengpid S, Villela EFM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682733>
30. **Ward renovation and PPE use procedures to protect medical staff from COVID-19 infection.** *J Infect Dev Ctries* 2020; 14:554-558Lin Z, Shu H, Jiang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683344>
31. **Environmental sampling for severe acute respiratory syndrome coronavirus 2 during COVID-19 outbreak in the Diamond Princess cruise ship.** *J Infect Dis* 2020; Yamagishi T, Ohnishi M, Matsunaga N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691828>
32. **Apparent and occult infections of medical staff in a COVID-19 designated hospital.** *J Infect Public Health* 2020; Li G, Hu C, He Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694083>
33. **The Role of Face Protection for Respiratory Viral Infections: A Historical Perspective.** *J Pediatric Infect Dis Soc* 2020; Cherry JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706367>
34. **Rigorous Hand Hygiene Practices Among Health Care Workers Reduce Hospital-Associated Infections During the COVID-19 Pandemic.** *J. Prim. Care Community Health* 2020;

- 11:2150132720943331Roshan R, Feroz AS, Rafique Z, Virani N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686571>
35. **Utility of a barrier enclosure in the management of a patient with coronavirus disease 2019 (COVID-19) for endoscopic retrograde cholangiopancreatography (ERCP) under sedation.** *Korean J Anesthesiol* 2020; Wee JZ, Lim V, See JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689760>
 36. **Copper-Alloy Surfaces and Cleaning Regimens against the Spread of SARS-CoV-2 in Dentistry and Orthopedics. From Fomites to Anti-Infective Nanocoatings.** *Materials (Basel)* 2020; 13:Poggio C, Colombo M, Arciola CR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707757>
 37. **Problems arising from PPE when worn for long periods.** *Med. Leg. J.* 2020;25817220935880Vidua RK, Chouksey VK, Bhargava DC, Kumar J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686980>
 38. **COVID-19 in the operating room: a review of evolving safety protocols.** *Patient Saf Surg* 2020; 14:30Prakash L, Dhar SA, Mushtaq M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695225>
 39. **COVID-19: Transmission in the incubation period.** *Pneumologie* 2020; 74:321-322Krome S.
 40. *Pneumologie* 2020; 74:315Schaberg T, Ewig S.
 41. **Safe performance of echocardiography during the COVID-19 pandemic: a practical guide.** *Rev Cardiovasc Med* 2020; 21:217-223Cameli M, Pastore MC, Henein M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706210>
 42. **Early implementation of protective measures defines surgical outcomes in the COVID-19 pandemic.** *Surg. Today* 2020; Senent-Boza A, Benítez-Linero I, Tallón-Aguilar L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700005>
 43. **A systematic review of viral transmission risk to healthcare staff comparing laparoscopic and open surgery.** *Surgeon* 2020; Patterson TJ, Currie PJ, Beck J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690463>
 44. **Potential challenges faced by blood bank services during COVID-19 pandemic and their mitigative measures: The Indian scenario.** *Transfus. Apher. Sci.* 2020:102877Arcot PJ, Kumar K, Mukhopadhyay T, Subramanian A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709475>
 45. **Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden.** *Ups. J. Med. Sci.* 2020:1-6Lidström AK, Sund F, Albinsson B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684119>
 46. **Neurosurgical Procedures and Safety During the COVID-19 Pandemic: A Case-Control Multi-Center Study.** *World Neurosurg* 2020; Bajunaid K, Alqurashi A, Alatar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702490>

Pulmonary disease (8 articles)

1. **Lung Injury in COVID-19-An Emerging Hypothesis.** *ACS Chem Neurosci* 2020; Alharthy A, Faqih F, Memish ZA, Karakitsos D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709193>
2. **COVID 19: Autopsy study confirms lung damage and risk of thromboembolism.** *Deutsche Medizinische Wochenschrift* 2020; 145:807-808Krome S.
3. **COVID-19 Pneumonia: Three Thoracic Complications in the Same Patient.** *Diagnostics (Basel)* 2020; 10Borghesi A, Aggiusti C, Farina D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698424>
4. **Unusual presentations of COVID-19 pneumonia on CT scans with spontaneous pneumomediastinum and loculated pneumothorax: A report of two cases and a review of the literature.** *Heart Lung* 2020; Brogna B, Bignardi E, Salvatore P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693960>
5. **Pneumothorax after COVID-19 pneumonia.** *MMW-Fortschritte der Medizin* 2020; 162:11Büttner R, Heiligensetzer A, Fürst A.
6. **Clinical features and chest CT findings of 3 cases of 2019 novel coronavirus (COVID-19) pneumonia.** *Radiol Case Rep* 2020; 15:1609-1613Hu X, Gou J, Guo L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685080>
7. **Incidental COVID-19 in the radiology department: Radiographic findings of COVID-19 in asymptomatic patient undergoing CT staging for breast cancer.** *Radiol Case Rep* 2020; 15:1614-1617Yoo K, Choi RY, Sun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685081>
8. **Pulmonary contusion during the COVID-19 pandemic: challenges in diagnosis and treatment.** *Surg. Today* 2020; Wang Y, Zeng C, Dong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700004>

Renal disease (22 articles)

1. **Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis.** *Can J Kidney Health Dis* 2020; 7:2054358120938573Lim MA, Pranata R, Huang I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685180>
2. **A brand-new cardiorenal syndrome in the COVID-19 setting.** *Clin Kidney J* 2020; 13:291-296Apetrii M, Enache S, Siriopol D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695320>
3. **Kidney disease and electrolytes in COVID-19: more than meets the eye.** *Clin Kidney J* 2020; 13:274-280Carriazo S, Kanbay M, Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699613>
4. **Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients.** *Clin Kidney J* 2020; 13:347-353Couturier A, Ferlicot S, Chevalier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695325>
5. **Coronavirus disease 2019 in chronic kidney disease.** *Clin Kidney J* 2020; 13:297-306D'Marco L, Puchades MJ, Romero-Parra M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699615>
6. **SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience.** *Clin Kidney J* 2020; 13:334-339Fontana F, Giaroni F, Frisina M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695323>
7. **Kidney manifestations of mild, moderate and severe coronavirus disease 2019: a retrospective cohort study.** *Clin Kidney J* 2020; 13:340-346Hong D, Long L, Wang AY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695324>

8. **Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury.** *Clin Kidney J* 2020; 13:362-370 Kormann R, Jacquot A, Alla A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695327>
9. **Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019.** *Clin Kidney J* 2020; 13:354-361 Rubin S, Orioux A, Prevel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695326>
10. **Clinical outcomes of hemodialysis patients infected with severe acute respiratory syndrome coronavirus 2 and impact of proactive chest computed tomography scans.** *Clin Kidney J* 2020; 13:328-333 Wang R, He H, Liao C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695322>
11. **Operational considerations for peritoneal dialysis management during the COVID-19 pandemic.** *Clin Kidney J* 2020; 13:322-327 Yang Z, Dong J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695321>
12. **The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients.** *J Clin Med* 2020; 9 Stock da Cunha T, Gomá-Garcés E, Avello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708750>
13. **Acute Kidney Injury and Kidney Damage in COVID-19 Patients.** *J Korean Med Sci* 2020; 35:e257 Na KR, Kim HR, Ham Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686373>
14. **COVID-19 and the kidney: what we think we know so far and what we don't.** *J Nephrol* 2020; Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691342>
15. **Coronavirus Disease 2019: Coronaviruses and Kidney Injury.** *J Urol* 2020; 101097ju0000000000001289 Lv W, Wu M, Ren Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693711>
16. **A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.** *Medicina (Kaunas)* 2020; 56 Marinaki S, Tsiakas S, Skalioti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708858>
17. **Protection of nephrology health professionals during the COVID-19 pandemic.** *Nefrologia* 2020; Arenas MD, Villar J, González C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703645>
18. **Management of peritoneal dialysis under COVID-19: The experience in Sichuan Province People's Hospital, China.** *Perit. Dial. Int.* 2020; 896860820935298 Chen J, Yin L, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703085>
19. **Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide.** *Transpl Infect Dis* 2020; e13425 Hu Q, Zhong Z, Xiong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702153>
20. **Kidney Transplant Recipients Infected By COVID-19: Review of the Initial Published Experience.** *Transpl Infect Dis* 2020; e13426 Moris D, Kesseli SJ, Barbas AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702150>
21. **Influence of Immunosuppression on Seroconversion Against SARS-Cov-2 in Two Kidney Transplant Recipients.** *Transpl Infect Dis* 2020; e13423 Wang AX, Quintero Cardona O, Ho DY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701196>
22. **The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success.** *Transplant Rev (Orlando)* 2020; 100567 Aziz F, Jorgenson MR, Garg N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690437>

Reviews (59 articles)

1. **The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.** *Adv. Exp. Med. Biol.* 2020; Paganini M, Bosco G, Perozzo FAG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696443>
2. **Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.** *Arch Med Res* 2020; Roshanravan N, Seif F, Ostadrahimi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682575>
3. **Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review.** *Brain Behav Immun* 2020; Egbert AR, Cankurtaran S, Karpiak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682993>
4. **Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review.** *Brain Behav Immun* 2020; Rita Egbert A, Cankurtaran S, Karpiak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682993>
5. **Overview of Management of Children with COVID-19.** *Clin Exp Pediatr* 2020; Wati DK, Manggala AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683801>
6. **Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients.** *Clin Kidney J* 2020; 13:347-353 Couturier A, Ferlicot S, Chevalier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695325>
7. **Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.** *Clin Microbiol Infect* 2020; Langford BJ, So M, Raybardhan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711058>
8. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48 Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
9. **Psoriasis and COVID-19: A narrative review with treatment considerations.** *Dermatol Ther* 2020; e13858 Elmas OF, Demirbas A, Kutlu O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686245>
10. **Disseminated Intravascular Coagulation: A Devastating Systemic Disorder of Special Concern with COVID-19.** *Dermatol Ther* 2020; Singh P, Schwartz RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700813>
11. **COVID-19: Current prediction models unsuitable for practical use.** *Deutsche Medizinische Wochenschrift* 2020; 145:806-807 Lichert F.
12. **Diabetes and COVID-19: A systematic review on the current evidences.** *Diabetes Res Clin Pract* 2020; 108347 Abdi A, Jalilian M, Ahmadi Sarbarzeh P, Vlasisavljevic Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711003>
13. **COVID-19-associated coagulopathy.** *Diagnosis (Berl)* 2020; Franchini M, Marano G, Cruciani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683333>
14. **Kawasaki disease in siblings and a review of drug treatment.** *Drugs Context* 2020; 9 Loo SK, Hon KL, Leung AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699547>

15. **COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus.** *Eur. J. Med. Chem.* 2020; 203:112647Kouznetsov VV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693298>
16. **Advances in the possible treatment of COVID-19: A review.** *Eur. J. Pharmacol.* 2020:173372Chibber P, Haq SA, Ahmed I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682787>
17. **Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.** *Expert Rev. Anti Infect. Ther.* 2020; Infante M, Ricordi C, Alejandro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693652>
18. **Factors Influencing Global Variations in COVID-19 Cases and Fatalities; A Review.** *Healthcare (Basel)* 2020; 8Abu Hammad O, Alnazzawi A, Borzangy SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708986>
19. **Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: A case report and literature review.** *Heart Lung* 2020; Khatri A, Wallach F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693958>
20. **Immune Responses to the Novel Coronavirus-2: Friend or Foe?** *Immunol. Invest.* 2020:1-3Mahmoodpoor A, Nader ND. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689852>
21. **Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review.** *Infect Dis Poverty* 2020; 9:100Fakheran O, Dehghannejad M, Khademi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698862>
22. **Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.** *Int Immunopharmacol* 2020; 86:106738Noorimotlagh Z, Karami C, Mirzaee SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683296>
23. **Physical and mental health impacts of COVID-19 on healthcare workers: a scoping review.** *Int. J. Emerg. Med.* 2020; 13:40Shaukat N, Ali DM, Razzak J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689925>
24. **COVID-19 and obstetric practice: A critical review of the Nigerian situation.** *Int J Gynaecol Obstet* 2020; Ijarotimi OA, Ubom AE, Olofinbiyi BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698245>
25. **Health Policy and Leadership Models During the COVID-19 Pandemic- Review Article.** *Int J Surg* 2020; Nicola M, Sohrabi C, Mathew G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687873>
26. **A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage.** *J. Clin. Lab. Anal.* 2020:e23483Zhao G, Su Y, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696465>
27. **Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns.** *J Clin Med* 2020; 9Koliaki C, Tentolouris A, Eleftheriadou I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708504>
28. **The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients.** *J Clin Med* 2020; 9Stock da Cunha T, Gomá-Garcés E, Avello A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708750>
29. **Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.** *J Crit Care* 2020; 59:176-190Cortegiani A, Ippolito M, Ingoglia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683212>
30. **Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.** *J. Drug Target.* 2020:1-35Akhtar S, Benter IF, Danjuma MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700580>
31. **Comparing Chinese children and adults with RT-PCR positive COVID-19: A systematic review.** *J Infect Public Health* 2020; Pei Y, Liu W, Masokano IB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682658>
32. **Cytokine storm syndrome in coronavirus disease 2019: A narrative review.** *J Intern Med* 2020; Gao YM, Xu G, Wang B, Liu BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696489>
33. **Vertical transmission of SARS CoV-2: a systematic review.** *J Matern Fetal Neonatal Med* 2020:1-8Deniz M, Tezer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693656>
34. **The mechanistic rationale of drugs, Primary endpoints, Geographical distribution of clinical trials against Severe acute respiratory syndrome-related coronavirus-2: A Systematic Review.** *J Med Virol* 2020; Venkatesulu BP, Thoguluva Chandrasekar V, Girdhar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706390>
35. **COVID-19 and the kidney: what we think we know so far and what we don't.** *J Nephrol* 2020; Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691342>
36. **A systematic review of neurological symptoms and complications of COVID-19.** *J. Neurol.* 2020; Chen X, Laurent S, Onur OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691236>
37. **The Role of Face Protection for Respiratory Viral Infections: A Historical Perspective.** *J Pediatric Infect Dis Soc* 2020; Cherry JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706367>
38. **Coronavirus Disease 2019 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission.** *J Reprod Infertil* 2020; 21:157-168Ashraf MA, Keshavarz P, Hosseinpour P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685412>
39. **Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.** *J Tradit Complement Med* 2020; 10:420-427Panyod S, Ho CT, Sheen LY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691006>
40. **Delaying Cancer Cases in Urology during COVID-19: Review of the Literature.** *J Urol* 2020:101097ju000000000001288Tachibana I, Ferguson EL, Mahenthiran A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692934>
41. **Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?** *mBio* 2020; 11Onishi JC, Häggblom MM, Shapses SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703911>
42. **Evaluation of Current Therapies for COVID-19 Treatment.** *Microorganisms* 2020; 8Sethi A, Bach H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707942>
43. **Telemedicine in Neurosurgery: Lessons Learned from a Systematic Review of the Literature for the COVID-19 Era and Beyond.** *Neurosurgery* 2020; Eichberg DG, Basil GW, Di L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687191>
44. **Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.** *Open Forum Infect Dis* 2020; 7:ofaa219Chastain DB, Stitt TM, Ly PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691007>

45. **Psychological burden of quarantine in children and adolescents: A rapid systematic review and proposed solutions.** *Pak J Med Sci* 2020; 36:1106-1116Imran N, Aamer I, Sharif MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704298>
46. **Potential role of platelets in COVID-19: Implications for thrombosis.** *Res Pract Thromb Haemost* 2020; 4:737-740Koupenova M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685881>
47. **Thrombosis and coagulopathy in COVID-19: An illustrated review.** *Res Pract Thromb Haemost* 2020; 4:744-751Levi M, Hunt BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685883>
48. **Epidemiologic, Clinical, and Laboratory Findings of the COVID-19 in the current pandemic.** *Res Sq* 2020; Xie Y, Wang Z, Liao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702720>
49. **Recurrent positive nucleic acid detection in a recovered COVID-19 patient: A case report and literature review.** *Respir Med Case Rep* 2020; 31:101152Geling T, Huaizheng G, Ying C, Hua H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704471>
50. **Prone cardiopulmonary resuscitation: A scoping and expanded grey literature review for the COVID-19 pandemic.** *Resuscitation* 2020; Douma MJ, Mackenzie E, Loch T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707142>
51. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** *Rev. Esp. Quimioter.* 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
52. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** *Rev. Esp. Quimioter.* 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
53. **Neuropathogenic human coronaviruses: A review.** *Rev Med Virol* 2020:e02118Abdelaziz OS, Waffa Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687681>
54. **Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol.** *Syst Rev* 2020; 9:161Thomas B, Pallivalapila A, El Kassem W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682444>
55. **COVID-19: Progress in diagnostics, therapy and vaccination.** *Theranostics* 2020; 10:7821-7835Liu X, Liu C, Liu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685022>
56. **SARS-CoV-2 infection in children.** *Turk Pediatri Ars* 2020; 55:95-102Cokugras H, Onal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684754>
57. **SARS-CoV-2 infection in children.** *Turk Pediatri Ars* 2020; 55:95-102Çokuğraş H, Önal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684754>
58. **Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable.** *Urol. Oncol.* 2020; Katims AB, Razdan S, Eilender BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703636>
59. **Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.** *Vascular* 2020:1708538120941635Sultan S, Acharya Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691699>

Risk factors (61 articles)

1. **Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions.** *Acta Med Port* 2020; Laires PA, Nunes C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707029>
2. **Alcohol: a probable risk factor of COVID-19 severity.** *Addiction* 2020; Saengow U, Assanangkornchai S, Casswell S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688440>
3. **ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.** *Ageing Res Rev* 2020:101123Viana SD, Nunes S, Reis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683039>
4. **Risk of death by age and gender from CoVID-19 in Peru, March-May, 2020.** *Ageing (Albany NY)* 2020; 12Munayco C, Chowell G, Tariq A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692724>
5. **Associations between hypovitaminosis D and COVID-19: a narrative review.** *Ageing Clin. Exp. Res.* 2020; Isaia G, Medico E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705585>
6. **COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants.** *Ageing Clin. Exp. Res.* 2020; Woolford SJ, D'Angelo S, Curtis EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705587>
7. **Risk of COVID-19 in oncohematological patients.** *Am. J. Blood Res.* 2020; 10:52-53Alcaraz R, Saiz-Rodríguez M, Cuevas B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685259>
8. **Risk of COVID-19 in oncohematological patients.** *Am. J. Blood Res.* 2020; 10:52-53Alcaraz R, Saiz-Rodríguez M, Cuevas B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685259>
9. **Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study.** *Am. J. Med. Sci.* 2020; 360:120-128Huang M, Yang Y, Shang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709280>
10. **Atopy is predictive of a decreased need for hospitalization for COVID-19.** *Ann. Allergy. Asthma. Immunol.* 2020; Keswani A, Dhana K, Rosenthal JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693208>
11. **Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm.** *Antioxidants (Basel)* 2020; 9Fakhouri EW, Peterson SJ, Kothari J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708430>
12. **De Ritis ratio and biochemical parameters in COVID-19 patients.** *Arch. Physiol. Biochem.* 2020:1-5Yazar H, Kayacan Y, Ozdin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683882>
13. **The significance of case detection ratios for predictions on the outcome of an epidemic - a message from mathematical modelers.** *Arch Public Health* 2020; 78:63Fuhrmann J, Barbarossa MV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685147>
14. **Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases.** *Biomarkers* 2020:1-36Kappert K, Jahić A, Tauber R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700561>
15. **Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 α /Glycolysis-Dependent Axis.** *Cell Metab.* 2020; Codo AC, Davanzo GG, Monteiro LB *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697943>
16. **Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes.** *Cells* 2020; 9Ahmadi P, Hartjen P, Kohsar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707842>
 17. **Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620943671Frydman GH, Boyer EW, Nazarian RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702995>
 18. **The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.** *Clin Hypertens* 2020; 26:14McLachlan CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685191>
 19. **Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?** *Clin Med (Lond)* 2020; Ladikou EE, Sivaloganathan H, Milne KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694169>
 20. **Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis.** *Crit Care* 2020; 24:459Chen XY, Huang MY, Xiao ZW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709251>
 21. **Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19.** *Crit Care* 2020; 24:452Kornilov SA, Lucas I, Jade K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698840>
 22. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
 23. **COVID-19: Current prediction models unsuitable for practical use.** *Deutsche Medizinische Wochenschrift* 2020; 145:806-807Lichert F.
 24. **Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis.** *Diabetes Res Clin Pract* 2020:108346Guo L, Shi Z, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710998>
 25. **Demographic and Clinical Features of Critically Ill Patients with COVID-19 in Greece: The Burden of Diabetes and Obesity.** *Diabetes Res Clin Pract* 2020:108331Halvatsiotis P, Kotanidou A, Tzannis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682810>
 26. **Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity.** *EBioMedicine* 2020; 58:102911Amrun SN, Lee CY, Lee B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711254>
 27. **Diagnostic groups and short-term outcomes in suspected COVID-19 cases treated in an emergency department.** *Emergencias* 2020; 32:242-252Martín-Sánchez FJ, González Del Castillo J, Valls Carbó A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692001>
 28. **Indoor air pollution (IAP) and pre-existing morbidities among under-5 children in India: are risk factors of coronavirus disease (COVID-19)?** *Environ Pollut* 2020; 266:115250Saha J, Chouhan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693324>
 29. **Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis.** *Environ. Sci. Pollut. Res. Int.* 2020; Malik VS, Ravindra K, Attri SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710359>
 30. **Epigenetic mechanisms regulating COVID-19 infection.** *Epigenetics* 2020; Chlamydas S, Papavassiliou AG, Piperi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686577>
 31. **Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.** *Febs j* 2020; Merzon E, Tworowski D, Gorohovski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700398>
 32. **Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis.** *Front Cell Infect Microbiol* 2020; 10:364Jesenak M, Brndiarova M, Urbancikova I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695683>
 33. **Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York.** *Geriatr Gerontol Int* 2020; 20:732-734Miyashita S, Yamada T, Mikami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691924>
 34. **ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults.** *Haematologica* 2020; Boudin L, Janvier F, Bylicki O, Dutasta F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703796>
 35. **Rethinking Air Quality and Climate Change after COVID-19.** *Int J Environ Res Public Health* 2020; 17Ching J, Kajino M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708953>
 36. **Decrease in Ambient Fine Particulate Matter during COVID-19 Crisis and Corresponding Health Benefits in Seoul, Korea.** *Int J Environ Res Public Health* 2020; 17Han C, Hong YC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707971>
 37. **Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain.** *Int J Environ Res Public Health* 2020; 17Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709002>
 38. **Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants.** *Int J Infect Dis* 2020; de Sousa E, Ligeiro D, Lérias JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693089>
 39. **The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity?** *Int J Mol Sci* 2020; 21Holuka C, Merz MP, Fernandes SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707661>
 40. **Role of neutrophil-lymphocyte-ratio in the mortality of males diagnosed with COVID-19.** *Iran J Microbiol* 2020; 12:194-197Belice T, Demir I, Yuksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685114>
 41. **Role of neutrophil-lymphocyte-ratio in the mortality of males diagnosed with COVID-19.** *Iran J Microbiol* 2020; 12:194-197Belice T, Demir I, Yuksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685114>
 42. **Interleukin-6-based mortality risk model for hospitalised COVID-19 patients.** *J Allergy Clin Immunol* 2020; Rocio LG, Alberto UR, Paloma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710975>
 43. **Geographic components of SARS-CoV-2 expansion: a hypothesis.** *J Appl Physiol (1985)* 2020; Joyce KE, Weaver SR, Lucas SJE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702272>

44. **ADHD as a Risk Factor for Infection With Covid-19.** *J Atten Disord* 2020;1087054720943271 Merzon E, Manor I, Rotem A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697120>
45. **The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.** *J Clin Med* 2020; 9Villard O, Morquin D, Molinari N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708205>
46. **Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort.** *J Gerontol A Biol Sci Med Sci* 2020; Atkins JL, Masoli JAH, Delgado J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687551>
47. **Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis.** *J Med Virol* 2020; Gao Y, Liu M, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687228>
48. **Ambient Air Pollution, Meteorology, and COVID-19 Infection in Korea.** *J Med Virol* 2020; Hoang T, Thi Anh TT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691877>
49. **ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.** *J Med Virol* 2020; Torre-Fuentes L, Matías-Guiu J, Hernández-Lorenzo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691890>
50. **Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.** *J Med Virol* 2020; van Gerwen M, Alsen M, Little C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706392>
51. **COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?** *J. Neurol.* 2020; Ferini-Strambi L, Salsone M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696341>
52. **Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.** *J. Physiol.* 2020; Siri-Angkul N, Chattipakorn SC, Chattipakorn N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710575>
53. **Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.** *Life Sci* 2020;118102Jafarzadeh A, Chauhan P, Saha B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687918>
54. **Corona pandemic: Obesity increases risk of severe course of COVID-19.** *MMW-Fortschritte der Medizin* 2020; 162:32-33Müssig K.
55. **Selenium Deficiency Is Associated with Mortality Risk from COVID-19.** *Nutrients* 2020; 12Moghaddam A, Heller RA, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708526>
56. **Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.** *Obes Rev* 2020; Foldi M, Farkas N, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686331>
57. **Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.** *Obes Rev* 2020; Földi M, Farkas N, Kiss S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686331>
58. **Insight into the Pediatric and Adult Dichotomy of COVID-19: Age-Related Differences in the Immune Response to SARS-CoV-2 infection.** *Pediatr Pulmonol* 2020; Fialkowski A, Gernez Y, Arya P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710693>
59. **Coronavirus disease 2019 mortality: a multivariate ecological analysis in relation to ethnicity, population density, obesity, deprivation and pollution.** *Public Health* 2020; 185:261-263Bray I, Gibson A, White J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693249>
60. **Continuously available ratio of SpO(2)/FiO(2) serves as a noninvasive prognostic marker for intensive care patients with COVID-19.** *Respir Res* 2020; 21:194Lu X, Jiang L, Chen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698822>
61. **Interferon: the invisible link between COVID-19 and BCGitis female protection?** *Scand. J. Immunol.* 2020:e12939Di Bella S, Cabas P, Antonello RM, Rizzo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697854>

Safety (11 articles)

1. **QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19.** *Cardiol. Young* 2020;1-15Tuncer T, Karaci M, Boga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686633>
2. **The syndrome of inappropriate antidiuresis in COVID-19 pneumonia: report of two cases.** *Clin Kidney J* 2020; 13:461-462Ravioli S, Niebuhr N, Ruchti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695328>
3. **Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?** *Cureus* 2020; 12:e8671Shover CL, Humphreys K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699671>
4. **Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients.** *Expert Rev. Cardiovasc. Ther.* 2020; Kow CS, Thiruchelvam K, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700573>
5. **An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.** *Food Chem. Toxicol.* 2020:111639Javorac D, Grahovac L, Manić L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707160>
6. **Hydroxychloroquine in Dermatology and Beyond: Recent Update.** *Indian Dermatol Online J* 2020; 11:453-464Sardana K, Sinha S, Sachdeva S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695719>
7. **Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.** *J Allergy Clin Immunol* 2020; Manjaly Thomas ZR, Leuppi-Taegtmeier A, Jamiolkowski D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710973>
8. **Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.** *J. Cardiovasc. Pharmacol. Ther.* 2020:1074248420935740Stremmel C, Kellnar A, Massberg S, Kääh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700555>
9. **Treating COVID-19: Review of drug hypersensitivity reactions.** *J. Investig. Allergol. Clin. Immunol.* 2020:0Dordal Culla MT, Herrera-Lasso Regás V, Martí-Garrido J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700681>

10. **Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.** *J Med Virol* 2020; Liu X, Liu Y, Chen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687223>
11. **Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.** *Vascular* 2020:1708538120941635 Sultan S, Acharya Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691699>

Treatment options (78 articles)

1. **The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.** *Adv. Exp. Med. Biol.* 2020; Paganini M, Bosco G, Perozzo FAG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696443>
2. **Inducible Epithelial Resistance Against Coronavirus Pneumonia in Mice.** *Am. J. Respir. Cell Mol. Biol.* 2020; Evans SE, Tseng CK, Scott BL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706609>
3. **Tongue diagnosis and treatment in traditional Chinese medicine for severe COVID-19: a case report.** *Ann Palliat Med* 2020; Liang K, Huang X, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692238>
4. **Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.** *Biochem. Pharmacol.* 2020:114169 Lisi L, Lacal PM, Barbaccia ML, Graziani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710969>
5. **PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.** *Biomed. Pharmacother.* 2020; 130:110536 Capoluongo E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32688139>
6. **Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19.** *Br. J. Clin. Pharmacol.* 2020; Dodds MG, Krishna R, Goncalves A, Rayner CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693436>
7. **THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.** *Br. J. Nutr.* 2020:1-37 Fiorino S, Zippi M, Gallo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703328>
8. **QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19.** *Cardiol. Young* 2020:1-15 Tuncer T, Karaci M, Boga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686633>
9. **Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.** *Cell. Signal.* 2020:109721 Poduri R, Joshi G, Jagadeesh G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711111>
10. **Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators.** *ChemMedChem* 2020; Gulotta MR, Lombino J, Perricone U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700795>
11. **The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.** *Chest* 2020; Yao JS, Paguio JA, Dee EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710890>
12. **Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.** *Clin Immunol* 2020:108544 Ibrahim H, Perl A, Smith D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707089>
13. **Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.** *Clin Infect Dis* 2020; Olender SA, Perez KK, Go AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706859>
14. **Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury.** *Clin Kidney J* 2020; 13:269-273 Ponce D, Balbi AL, Durand JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695319>
15. **Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?** *Cureus* 2020; 12:e8671 Shover CL, Humphreys K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699671>
16. **The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.** *Cureus* 2020; 12:e8631 Tadeipalli S, Vanjarapu JMR, De Dona A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685300>
17. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48 Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
18. **Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.** *Curr Med Chem* 2020; Laws M, Surani YM, Hasan MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693756>
19. **Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?** *Diagnosis (Berl)* 2020; Majbour N, El-Agnaf O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692700>
20. **Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.** *Eur. J. Clin. Pharmacol.* 2020; Ragia G, Manolopoulos VG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696234>
21. **COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus.** *Eur. J. Med. Chem.* 2020; 203:112647 Kouznetsov VV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693298>
22. **Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.** *Eur. J. Med. Chem.* 2020; 203:112653 Nebigil CG, Moog C, Vagner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693294>
23. **Advances in the possible treatment of COVID-19: A review.** *Eur. J. Pharmacol.* 2020:173372 Chibber P, Haq SA, Ahmed I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682787>
24. **Virology, pathogenesis, diagnosis and in-line treatment of COVID-19.** *Eur. J. Pharmacol.* 2020:173375 Samudrala PK, Kumar P, Choudhary K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682788>
25. **Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.** *Euro Surveill* 2020; 25Zheng Z, Monteil VM, Maurer-Stroh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700671>

26. **Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.** Expert Opin Biol Ther 2020; Loganathan S, Athalye SN, Joshi SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700604>
27. **Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.** Expert Rev. Anti Infect. Ther. 2020; Infante M, Ricordi C, Alejandro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693652>
28. **Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.** Expert Rev. Anti Infect. Ther. 2020; Tomaszewicz K, Piekarska A, Stempkowska-Rejek J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693650>
29. **Coronavirus disease 2019 drug discovery through molecular docking.** F1000Res 2020; 9:502Singh S, Florez H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704354>
30. **An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.** Food Chem. Toxicol. 2020:111639Javorac D, Grahovac L, Manić L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707160>
31. **Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.** Future Med. Chem. 2020; Pawelczyk A, Zaprutko L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698626>
32. **Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.** Haematologica 2020; Perotti C, Baldanti F, Bruno R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703797>
33. **Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.** IDCases 2020; 21:e00888Antony SJ, Singh J, de Jesus M, Lance J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685369>
34. **Deciphering the co-adaptation of codon usage between respiratory coronaviruses and their human host uncovers candidate therapeutics for COVID-19.** Infect Genet Evol 2020:104471Nambou K, Anakpa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707288>
35. **Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.** Int J Antimicrob Agents 2020:106101Khuroo MS, Sofi AA, Khuroo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687949>
36. **Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?** Int J Mol Sci 2020; 21:Menegazzi M, Campagnari R, Bertoldi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708322>
37. **Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results.** Int. J. Radiat. Oncol. Biol. Phys. 2020; Ameri A, Rahnama N, Bozorgmehr R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707264>
38. **Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.** J Allergy Clin Immunol 2020; Manjaly Thomas ZR, Leuppi-Taegtmeier A, Jamiolkowski D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710973>
39. **In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M(pro)) from flavonoid based phytochemical constituents of Calendula officinalis.** J Biomol Struct Dyn 2020:1-16Das P, Majumder R, Mandal M, Basak P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705952>
40. **Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants.** J Biomol Struct Dyn 2020:1-23Fatoki TH, Ibraheem O, Ogunyemi IO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32686993>
41. **Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.** J Biomol Struct Dyn 2020:1-7Fiorucci D, Milletti E, Orofino F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705942>
42. **In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors.** J Biomol Struct Dyn 2020:1-12Ibrahim MAA, Abdelrahman AHM, Hegazy MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684114>
43. **Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.** J Biomol Struct Dyn 2020:1-16Razzaghi-Asl N, Ebadi A, Shahabipour S, Gholamin D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705953>
44. **Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.** J. Cardiovasc. Pharmacol. Ther. 2020:1074248420935740Stremmel C, Kellnar A, Massberg S, Käab S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700555>
45. **Stem cell therapies for COVID-19: Strategy and application.** J. Cell. Biochem. 2020; Darabi R, Li Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692858>
46. **Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.** J Crit Care 2020; 59:176-190Cortegiani A, Ippolito M, Ingoglia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683212>
47. **Rituximab: a safe therapeutic option during the COVID-19 pandemic?** J Dermatolog Treat 2020:1-3Di Altobrando A, Patrizi A, Abbenante D, Bardazzi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697610>
48. **Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.** J. Drug Target. 2020:1-35Akhtar S, Benter IF, Danjuma MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700580>
49. **An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.** J Infect Public Health 2020; Wang D, Li Z, Liu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684351>
50. **Treating COVID-19: Review of drug hypersensitivity reactions.** J. Investig. Allergol. Clin. Immunol. 2020:0Dordal Culla MT, Herrera-Lasso Regás V, Martí-Garrido J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700681>
51. **The mechanistic rationale of drugs, Primary endpoints, Geographical distribution of clinical trials against Severe acute respiratory syndrome-related coronavirus-2: A Systematic Review.** J Med Virol 2020; Venkatesulu BP, Thoguluva Chandrasekar V, Girdhar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706390>
52. **Using "old" medications to fight new COVID-19: Re-purposing with a purpose.** J. Mol. Cell. Cardiol. 2020; Wang Y, Foo R, Thum T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687852>

53. **Benzothiazoles as potential antiviral agents.** *J. Pharm. Pharmacol.* 2020; Asiri YI, Alsayari A, Muhsinah AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32705690>
54. **Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian's perspective.** *J Pharm Policy Pract* 2020; 13:45Bayoumy AB, de Boer NKH, Ansari AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695427>
55. **The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?** *J Tradit Complement Med* 2020; 10:405-419Fuzimoto AD, Isidoro C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691005>
56. **Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.** *J Tradit Complement Med* 2020; 10:420-427Panyod S, Ho CT, Sheen LY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691006>
57. **An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.** *Life Sci* 2020;118105Jamwal S, Gautam A, Elsworth J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687917>
58. **Evaluation of Current Therapies for COVID-19 Treatment.** *Microorganisms* 2020; 8Sethi A, Bach H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707942>
59. **Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.** *Open Forum Infect Dis* 2020; 7:ofaa219Chastain DB, Stitt TM, Ly PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691007>
60. **Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.** *PeerJ* 2020; 8:e9533Wang Z, Wang Y, Vilekar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704455>
61. **Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.** *Pharmacol. Rep.* 2020; Rogosnitzky M, Okediji P, Koman I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32700247>
62. **Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.** *Proc Natl Acad Sci U S A* 2020; Cauchois R, Koubi M, Delarbre D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32699149>
63. **In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.** *Res Sq* 2020; Das S, Camphausen K, Shankavaram U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702730>
64. **Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.** *Respirology* 2020; McCarthy C, Savinelli S, Feeney ER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696570>
65. **Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.** *SLAS Discov* 2020:2472555220945281Banday AH, Shameem SA, Ajaz SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692266>
66. **Cellular Therapy: Shafts of Light Emerging for COVID-19.** *Stem Cell Investig* 2020; 7:11Jeyaraman M, Ranjan R, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32695804>
67. **Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.** *Stem Cell. Res. Ther.* 2020; 11:305Xiao K, Hou F, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698898>
68. **Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol.** *Syst Rev* 2020; 9:161Thomas B, Pallivalapila A, El Kassem W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682444>
69. **Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen.** *Ther. Clin. Risk Manag.* 2020; 16:617-629Mirjalili M, Shafiekhani M, Vazin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694915>
70. **COVID-19: Progress in diagnostics, therapy and vaccination.** *Theranostics* 2020; 10:7821-7835Liu X, Liu C, Liu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685022>
71. **Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.** *Transfus. Apher. Sci.* 2020:102875Abolghasemi H, Eshghi P, Cheraghali AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694043>
72. **Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.** *Transfus. Apher. Sci.* 2020:102871Karataş A, İnkaya A, Demiroğlu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694044>
73. **International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection.** *Transfus Med Rev* 2020; Murphy M, Estcourt L, Grant-Casey J, Dzik S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703664>
74. **The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.** *Turk J Med Sci* 2020; Tanriverd IE, M CO, Yildirim BZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682360>
75. **The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.** *Turk J Med Sci* 2020; Tanriverd E, ÇÖrtük M, Yildirim BZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682360>
76. **Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.** *Vascular* 2020:1708538120941635Sultan S, Acharya Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691699>
77. **A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.** *Viral Sin* 2020; Hu K, Wang M, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696396>
78. **Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.** *Viruses* 2020; 12Kang K, Kim HH, Choi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698440>

Trials (17 articles)

1. **The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.** *Chest* 2020; Yao JS, Paguio JA, Dee EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710890>
2. **Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.** *Clin Infect Dis* 2020; Olender SA, Perez KK, Go AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706859>

3. **Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.** *Expert Rev. Anti Infect. Ther.* 2020; Tomasiewicz K, Piekarska A, Stempkowska-Rejek J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693650>
4. **Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.** *Haematologica* 2020; Perotti C, Baldanti F, Bruno R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703797>
5. **Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain.** *Int J Environ Res Public Health* 2020; 17 Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32709002>
6. **Acquired infection after intubating patients with COVID-19: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 67:110006 Zhang J, Sun M, Li N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711351>
7. **Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain.** *J. Clin. Hypertens. (Greenwich)* 2020; Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710674>
8. **The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.** *J Clin Med* 2020; 9 Villard O, Morquin D, Molinari N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32708205>
9. **Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial study (COVID in Older PEople).** *J Hosp Infect* 2020; Carter B, Collins JT, Barlow-Pay F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702463>
10. **Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.** *J Med Virol* 2020; Liu X, Liu Y, Chen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687223>
11. **The mechanistic rationale of drugs, Primary endpoints, Geographical distribution of clinical trials against Severe acute respiratory syndrome-related coronavirus-2: A Systematic Review.** *J Med Virol* 2020; Venkatesulu BP, Thoguluva Chandrasekar V, Girdhar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706390>
12. **Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.** *Transfus. Apher. Sci.* 2020:102875 Abolghasemi H, Eshghi P, Cheraghali AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32694043>
13. **A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.** *Transfus Med Rev* 2020; Liao G, Zheng K, Lalu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684483>
14. **International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection.** *Transfus Med Rev* 2020; Murphy M, Estcourt L, Grant-Casey J, Dzik S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703664>
15. **Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:666 Daval M, Corré A, Palpacuer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32690074>
16. **The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.** *Turk J Med Sci* 2020; Tanriverd IE, M CO, Yildirim BZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682360>
17. **A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.** *Virology* 2020; Hu K, Wang M, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696396>

Vaccines (15 articles)

1. **Designing Pull Funding For A COVID-19 Vaccine.** *Health Aff (Millwood)* 2020:101377hlthaff202000646 Snyder CM, Hoyt K, Gouglas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701395>
2. **A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States.** *Health Secur* 2020; Brunson EK, Schoch-Spana M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706599>
3. **YouTube coverage of COVID-19 vaccine development: implications for awareness and uptake.** *Hum Vaccin Immunother* 2020:1-4 Basch CH, Hillyer GC, Zagnit EA, Basch CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32701403>
4. **Promise and challenges in the development of COVID-19 vaccines.** *Hum Vaccin Immunother* 2020:1-5 Chen W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703069>
5. **COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.** *Hum Vaccin Immunother* 2020:1-14 Iqbal Yatoo M, Hamid Z, Parray OR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703064>
6. **Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases.** *Hum Vaccin Immunother* 2020:1-8 Puri N, Coomes EA, Haghbayan H, Gunaratne K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693678>
7. **COVID-19 - Important considerations for developing and using a vaccine.** *Hum Vaccin Immunother* 2020:1-2 Rahman IU, Ali N, Ijaz F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693665>
8. **SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.** *J Med Virol* 2020; Wang Y, Wang L, Cao H, Liu C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691875>
9. **An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein.** *Res Sq* 2020; Ghafouri F, Cohan RA, Noorbakhsh F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32702713>
10. **Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.** *SLAS Discov* 2020:2472555220945281 Bandy AH, Shameem SA, Ajaz SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692266>
11. **COVID-19: Progress in diagnostics, therapy and vaccination.** *Theranostics* 2020; 10:7821-7835 Liu X, Liu C, Liu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685022>

12. **Planning for COVID-19 vaccines safety surveillance.** *Vaccine* 2020; Kochhar S, Salmon DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684499>
13. **A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.** *Vaccine* 2020; Privor-Dumm LA, Poland GA, Barratt J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32703743>
14. **Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.** *Vaccines (Basel)* 2020; 8Corral-Lugo A, López-Siles M, López D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698423>
15. **COVID-19: Mechanisms of Vaccination and Immunity.** *Vaccines (Basel)* 2020; 8Speiser DE, Bachmann MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32707833>

Women – pregnancy (27 articles)

1. **Clinical Molecular Genetics Evaluation in Women with Reproductive Failures.** *Am. J. Reprod. Immunol.* 2020:e13313Bilal MY, Katara G, Dambaeva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710571>
2. **COVID-19: Current and future crisis planning in breast imaging.** *Breast J* 2020; Gerlach K, Phalak K, Patel M, Leung JWT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683734>
3. **Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: A case series.** *Case Rep Womens Health* 2020; 27:e00243Richtmann R, Torloni MR, Oyamada Otani AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32704477>
4. **Berlin, April 22, 2020 - Don't be afraid of hospital treatment or hospital births in times of COVID-19.** *Geburtshilfe Frauenheilkd.* 2020; 80:579-580Scharl A, Albring C.
5. **Pregnancy, birth, and puerperium with SARS-CoV-2 and COVID-19.** *Gynakologe* 2020; Hagenbeck C, Pecks U, Fehm T *et al.*
6. **Contraceptive Mandate, ACA Final Rules, And COVID-19.** *Health Aff (Millwood)* 2020:101377Hlhaff202001265Keith K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32687416>
7. **Third Trimester Placentas of SARS-CoV-2-Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization.** *Histopathology* 2020; Smithgall MC, Liu-Jarin X, Hamele-Bena D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692408>
8. **Providing women's health care during COVID-19: Personal and professional challenges faced by health workers.** *Int J Gynaecol Obstet* 2020; Green L, Fateen D, Gupta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692854>
9. **COVID-19 and obstetric practice: A critical review of the Nigerian situation.** *Int J Gynaecol Obstet* 2020; Ijarotimi OA, Ubom AE, Olofinbiyi BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698245>
10. **Worldwide maternal deaths due to COVID-19: A brief review.** *Int J Gynaecol Obstet* 2020; Nakamura-Pereira M, Andreucci CB, de Oliveira Menezes M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706925>
11. **SARS-CoV-2 in pregnancy: characteristics and outcomes of hospitalized and non-hospitalized women due to COVID-19.** *J Matern Fetal Neonatal Med* 2020:1-7Barbero P, Muguerza L, Herraiz I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32689846>
12. **Vertical transmission of SARS CoV-2: a systematic review.** *J Matern Fetal Neonatal Med* 2020:1-8Deniz M, Tezer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32693656>
13. **Perinatal management of SARS-CoV-2 infection in a level III University Hospital.** *J Matern Fetal Neonatal Med* 2020:1-4Pissarra S, Rosário M, Moucho M, Soares H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32698646>
14. **Outcomes of universal SARS-CoV-2 testing program in pregnant women admitted to hospital and the adjuvant role of lung ultrasound in screening: A prospective cohort study.** *J Matern Fetal Neonatal Med* 2020:1-22Yassa M, Yirmibes C, Cavusoglu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691641>
15. **COVID-19 and pregnancy: an opportunity to correct an historic gender bias.** *J Med Virol* 2020; Comas C, Carreras E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32706391>
16. **Feasibility and safety of urgently initiated maternal telemedicine in response to the spread of COVID-19: A 1-month report.** *J. Obstet. Gynaecol. Res.* 2020; Nakagawa K, Umazume T, Mayama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691488>
17. **Academic clinical learning environment in obstetrics and gynecology during the COVID-19 pandemic: responses and lessons learned.** *J. Perinat. Med.* 2020; Olson HL, Towner D, Hiraoka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32692706>
18. **Coronavirus Disease 2019 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission.** *J Reprod Infertil* 2020; 21:157-168Ashraf MA, Keshavarz P, Hosseinpour P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32685412>
19. **Syndemic Perspectives to Guide Black Maternal Health Research and Prevention During the COVID-19 Pandemic.** *Matern Child Health J* 2020; Lemke MK, Brown KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32696248>
20. **Statewide Implementation of Virtual Perinatal Home Visiting During COVID-19.** *Matern Child Health J* 2020; Marshall J, Kihlström L, Buro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32691359>
21. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** *Rev. Esp. Quimioter.* 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
22. **[Scoping review of coronavirus case series (SARS-CoV, MERS-CoV and SARS-CoV-2) and their obstetric and neonatal results].** *Rev. Esp. Quimioter.* 2020; Rodríguez-Blanco N, Vegara-Lopez I, Aleo-Giner L, Tuells J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32683837>
23. **Interferon: the invisible link between COVID-19 and BCGitis female protection?** *Scand. J. Immunol.* 2020:e12939Di Bella S, Cabas P, Antonello RM, Rizzo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32697854>
24. **Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol.** *Syst Rev* 2020; 9:161Thomas B, Pallivalapila A, El Kassem W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682444>
25. **The Turkish Neonatal Society proposal for the management of COVID-19 in the neonatal intensive care unit.** *Turk Pediatri Ars* 2020; 55:86-92Erdeve O, Cetinkaya M, Bas AY *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=32684752>

26. **The Turkish Neonatal Society proposal for the management of COVID-19 in the neonatal intensive care unit.** *Turk Pediatri Ars* 2020; 55:86-92 Erdeve Ö, Çetinkaya M, Baş AY *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=32684752>

27. **Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy.** *Women Birth* 2020; Ravaldi C, Wilson A, Ricca V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32684343>

to subscribe click [here](#)
